<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="5001b104-2557-499d-bf89-0a01149937a9"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use TOUJEO<sup>®</sup> U-300 safely and effectively. See full prescribing information for TOUJEO<sup>®</sup> U-300. <br/>
      <br/> TOUJEO U-300 (insulin glargine) injection, for subcutaneous use<br/> Initial U.S. Approval: 2015</title>
   <effectiveTime value="20250312"/>
   <setId root="c9561d96-124d-48ca-982f-0aa1575bff36"/>
   <versionNumber value="24"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="824676584" root="1.3.6.1.4.1.519.1"/>
            <name>Sanofi-Aventis U.S. LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="313218430" root="1.3.6.1.4.1.519.1"/>
                        <name>Sanofi-Aventis Deutschland GmbH</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5869" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5871" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5869" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5871" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5869" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5871" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5869" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5871" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="050424395" root="1.3.6.1.4.1.519.1"/>
                        <name>Genzyme Corporation</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5871" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0024-5871" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="42503120-5e77-4eef-a6b6-0cf928037b9e"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20240831"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0024-5869" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>TOUJEO</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>insulin glargine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="300" unit="U"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="2ZM8CX04RZ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>insulin glargine</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="2ZM8CX04RZ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>insulin glargine</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="90" unit="ug"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="J41CSQ7QDS" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>zinc</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="2.7" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="GGO4Y809LO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>metacresol</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="20" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="PDC6A3C0OX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>glycerin</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1.5" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0024-5869-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="3" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0024-5869-03" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20150215"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="1.5" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0024-5869-00" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C96974" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20150215"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="BLA206538" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20150215"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0024-5871" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>TOUJEO Max</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>insulin glargine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="300" unit="U"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="2ZM8CX04RZ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>insulin glargine</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="2ZM8CX04RZ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>insulin glargine</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="90" unit="ug"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="J41CSQ7QDS" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>zinc</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="2.7" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="GGO4Y809LO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METACRESOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="20" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="PDC6A3C0OX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="3" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0024-5871-00" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="2" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0024-5871-02" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20180326"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="3" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0024-5871-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C96974" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20180326"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="BLA206538" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20150215"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="e89925b6-af75-4a44-91bd-9ae67e7bfa0b"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>TOUJEO is indicated to improve glycemic control in adults and pediatric patients 6 years of age and older with diabetes mellitus.</paragraph>
               </text>
               <effectiveTime value="20240831"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>TOUJEO is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients 6 years and older with diabetes mellitus. (<linkHtml href="#S1">1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use</content>:</paragraph>
                        <paragraph>Not recommended for the treatment of diabetic ketoacidosis. (<linkHtml href="#S1">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section>
                     <id root="e85a718a-9211-4eb0-aa7a-290cf8fe2cc5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use:</content>
                        </paragraph>
                        <paragraph>TOUJEO is not recommended for the treatment of diabetic ketoacidosis.</paragraph>
                     </text>
                     <effectiveTime value="20240831"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="981886ec-bb24-4780-8453-169bccee763c"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20240831"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Individualize dose based on type of diabetes, metabolic needs, blood glucose monitoring results and glycemic control goal. (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                           <item>Administer subcutaneously into the abdominal area, thigh, or deltoid once daily at any time during the day, at the same time every day. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>Rotate injection sites to reduce risk of lipodystrophy and localized cutaneous amyloidosis. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>Do not dilute or mix with any other insulin or solution. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>See Full Prescribing Information for the recommended starting dosage in patients with type 2 diabetes and how to switch to TOUJEO from other insulins (<linkHtml href="#S2.3">2.3</linkHtml>, <linkHtml href="#S2.4">2.4</linkHtml>)</item>
                           <item>Closely monitor glucose when switching to TOUJEO and during initial weeks thereafter. (<linkHtml href="#S2.4">2.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="3382b3e5-2221-4fc1-8f57-d355d1546c57"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1	Important Administration Instructions</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Always check insulin labels before administration <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>.</item>
                           <item>Visually inspect the TOUJEO solution for particulate matter and discoloration prior to administration and only use if the solution is clear and colorless with no visible particles.</item>
                           <item>Inject TOUJEO subcutaneously into the abdominal area, thigh, or deltoid.</item>
                           <item>Rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>, <linkHtml href="#S6">Adverse Reactions (6)</linkHtml>]</content>.</item>
                           <item>Use TOUJEO with caution in patients with visual impairment who may rely on audible clicks to dial their dose.</item>
                           <item>Do not administer TOUJEO intravenously or in an insulin pump.</item>
                           <item>Do not dilute or mix TOUJEO with any other insulin products or solutions.</item>
                           <item>Never transfer TOUJEO from the cartridges of the TOUJEO SoloStar or TOUJEO Max SoloStar prefilled pen into a syringe for administration <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>.</item>
                        </list>
                     </text>
                     <effectiveTime value="20240831"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="6b67d5fa-0701-4aa5-b3ba-108b97ffb73d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2	General Dosing Instructions</title>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>TOUJEO is available in 2 single-patient-use prefilled pens:<list listType="unordered" styleCode="circle">
                                 <item>The TOUJEO SoloStar prefilled pen contains 450 units of insulin glargine. It delivers doses in 1-unit increments and can deliver up to 80 units in a single injection.</item>
                                 <item>The TOUJEO Max SoloStar prefilled pen contains 900 units of insulin glargine. It delivers doses in 2-unit increments and can deliver up to 160 units in a single injection. It is recommended for patients requiring at least 20 units per day.</item>
                              </list>
                           </item>
                           <item>When changing between TOUJEO SoloStar and TOUJEO Max SoloStar, if the patient's previous dose was an odd number, the dose should be increased or decreased by 1 unit to match the dose increments dialable on each prefilled pen.</item>
                           <item>The dose counter of the TOUJEO SoloStar or TOUJEO Max SoloStar prefilled pen shows the number of units of TOUJEO to be injected and no conversion is required.</item>
                           <item>Inject TOUJEO subcutaneously once a day at the same time of day.</item>
                           <item>During changes to a patient's insulin regimen, increase the frequency of blood glucose monitoring <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</item>
                           <item>Individualize and titrate the dosage of TOUJEO based on the patient's metabolic needs, blood glucose monitoring results, and glycemic control goal.</item>
                           <item>Titrate the dose of TOUJEO no more frequently than every 3 to 4 days.</item>
                           <item>Dosage adjustments may be needed with changes in physical activity, changes in meal patterns (i.e., macronutrient content or timing of food intake), changes in renal or hepatic function or during acute illness to minimize the risk of hypoglycemia or hyperglycemia <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml> and <linkHtml href="#S8.6">Use in Specific Populations (8.6</linkHtml>, <linkHtml href="#S8.7">8.7)</linkHtml>]</content>.</item>
                        </list>
                     </text>
                     <effectiveTime value="20240831"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="bf41cbb2-3df2-4def-bcff-87a04500cdcc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3	Starting Dose in Insulin-Naive Pediatric and Adult Patients</title>
                     <effectiveTime value="20240831"/>
                     <component>
                        <section>
                           <id root="b79c9113-91d4-405b-b95b-bbe8bb5b0795"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Recommended Starting Dosage in Patients with Type 1 Diabetes</content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>The recommended starting dose of TOUJEO in insulin-naive patients with type 1 diabetes is approximately one-third to one-half of the total daily insulin dose. The remainder of the total daily insulin dose should be given as a short-acting insulin and divided between each daily meal. As a general rule, 0.2 to 0.4 units of insulin per kilogram of body weight can be used to calculate the initial total daily insulin dose in insulin-naive patients with type 1 diabetes.</item>
                                 <item>The maximum glucose lowering effect of a dose of TOUJEO may take five days to fully manifest and the first dose may be insufficient to cover metabolic needs in the first 24 hours of use <content styleCode="italics">[see <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>]</content>. When initiating TOUJEO, monitor glucose daily.</item>
                              </list>
                           </text>
                           <effectiveTime value="20240831"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="48c42f5a-7234-483d-976a-c89d73717ad1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Recommended Starting Dosage in Patients with Type 2 Diabetes</content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>The recommended starting dose of TOUJEO in insulin-naive patients with type 2 diabetes is 0.2 units per kilogram of body weight once daily.</item>
                              </list>
                           </text>
                           <effectiveTime value="20240831"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="7a238ff0-bfbc-4747-b284-e1fe682844b2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4	Starting Dose in Pediatric and Adult Patients with Either Type 1 or Type 2 Diabetes Already on Insulin Therapy</title>
                     <text>
                        <paragraph>Dosage adjustments are recommended to lower the risk of hypoglycemia when switching patients to TOUJEO from another insulin therapy <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>].</content>
                        </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>For patients currently on once-daily long or intermediate-acting insulin, start TOUJEO at the same unit dose as the once-daily long-acting insulin dose. For patients controlled on LANTUS (insulin glargine, 100 units/mL), expect that a higher daily dose of TOUJEO will be needed to maintain the same level of glycemic control <content styleCode="italics">[see <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml> and <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>]</content>.</item>
                           <item>For patients currently on twice-daily long or intermediate-acting insulin, start TOUJEO at 80% of the total daily NPH or insulin detemir twice-daily dosage.</item>
                           <item>When switching patients to TOUJEO, monitor glucose frequently in the first weeks of therapy <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml> and <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>]</content>. 									</item>
                        </list>
                     </text>
                     <effectiveTime value="20240831"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="77bbb402-658c-4c07-a5e5-46c18230f3b4"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Injection: 300 units/mL (U-300) of insulin glargine in a clear, colorless, solution available as:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>1.5 mL SoloStar single-patient-use prefilled pen (450 units per 1.5 mL pen)</item>
                     <item>3 mL Max SoloStar single-patient-use prefilled pen (900 units per 3 mL pen)</item>
                  </list>
               </text>
               <effectiveTime value="20240831"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection: 300 units/mL (U-300) insulin glargine in:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>1.5 mL SoloStar single-patient-use prefilled pen (<linkHtml href="#S3">3</linkHtml>)</item>
                           <item>3 mL Max SoloStar single-patient-use prefilled pen (<linkHtml href="#S3">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="2a69a88c-301f-473a-b3c2-5ca7189c05e2"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>TOUJEO is contraindicated:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>During episodes of hypoglycemia <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>.</item>
                     <item>In patients with hypersensitivity to insulin glargine or any excipients in TOUJEO <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>.</item>
                  </list>
               </text>
               <effectiveTime value="20240831"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>During episodes of hypoglycemia (<linkHtml href="#S4">4</linkHtml>)</item>
                           <item>Hypersensitivity to insulin glargine or any excipients in TOUJEO (<linkHtml href="#S4">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="56afdc11-ddc1-4ecd-8b60-4d69ec4e496f"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20240831"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="italics">Never share</content> a TOUJEO SoloStar or TOUJEO Max SoloStar single-patient-use prefilled pen between patients, even if the needle is changed. (<linkHtml href="#S5.1">5.1</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Hyperglycemia or hypoglycemia with changes in insulin regimen:</content> Make changes to a patient's insulin regimen (e.g., insulin strength, manufacturer, type, injection site, or method of administration) under close medical supervision with increased frequency of blood glucose monitoring. (<linkHtml href="#S5.2">5.2</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Hypoglycemia:</content> May be life-threatening. Increase frequency of glucose monitoring with changes to: insulin dosage, concomitant drugs, meal pattern, physical activity, and in patients with renal impairment or hepatic impairment or hypoglycemia unawareness. (<linkHtml href="#S5.3">5.3</linkHtml>, <linkHtml href="#S6.1">6.1</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Hypoglycemia Due to Medication errors:</content> Accidental mix-ups between insulin products can occur. Instruct patients to check insulin labels before injection. (<linkHtml href="#S5.4">5.4</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Hypersensitivity reactions:</content> Severe, life-threatening, generalized allergy, including anaphylaxis, can occur. Discontinue TOUJEO, monitor and treat if indicated. (<linkHtml href="#S5.5">5.5</linkHtml>, <linkHtml href="#S6.1">6.1</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Hypokalemia:</content> May be life-threatening. Monitor potassium levels in patients at risk of hypokalemia and treat if indicated. (<linkHtml href="#S5.6">5.6</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Fluid retention and heart failure with concomitant use of Thiazolidinediones (TZDs):</content> Observe for signs and symptoms of heart failure; consider dosage reduction or discontinuation if heart failure occurs. (<linkHtml href="#S5.7">5.7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="a03269e1-6f76-4330-b9be-8d1f07ba7f92"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1	Never Share a TOUJEO SoloStar or TOUJEO Max SoloStar Pen Between Patients</title>
                     <text>
                        <paragraph>TOUJEO SoloStar or TOUJEO Max SoloStar single-patient-use prefilled pens must never be shared between patients, even if the needle is changed. Pen sharing poses a risk for transmission of blood-borne pathogens.</paragraph>
                     </text>
                     <effectiveTime value="20240831"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="8cd730f0-7f2b-4d7f-a54e-8f63f9bb6a0f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2	Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen</title>
                     <effectiveTime value="20240831"/>
                     <component>
                        <section>
                           <id root="eb9eb399-e8cb-4b1d-b1f9-1be100d602a1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Changes in Insulin Regimen Including Changes to Administration Site</content>
                              </paragraph>
                              <paragraph>Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, injection site, or method of administration) may affect glycemic control and predispose to hypoglycemia <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content> or hyperglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia, and a sudden change in the injection site (to unaffected area) has been reported to result in hypoglycemia <content styleCode="italics">[see <linkHtml href="#S6">Adverse Reactions (6)</linkHtml>]</content>.</paragraph>
                              <paragraph>Make any changes to a patient's insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia. For patients with type 2 diabetes, dosage adjustments of concomitant oral antidiabetic products may be needed.</paragraph>
                           </text>
                           <effectiveTime value="20240831"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="268176d1-84fd-460d-9bb4-5bc8b2762c53"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Changing to TOUJEO from other Insulin Therapies</content>
                              </paragraph>
                              <paragraph>On a unit-to-unit basis, TOUJEO has a lower glucose lowering effect than LANTUS <content styleCode="italics">[see <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>]</content>. In clinical trials, patients who changed to TOUJEO from other basal insulins experienced higher average fasting plasma glucose levels in the first weeks of therapy compared to patients who were changed to LANTUS. Higher doses of TOUJEO were required to achieve similar levels of glucose control compared to LANTUS in clinical trials <content styleCode="italics">[see <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>]</content>. 										</paragraph>
                              <paragraph>The onset of action of TOUJEO develops over 6 hours following an injection. In type 1 diabetes patients treated with IV insulin, consider the longer onset of action of TOUJEO before stopping IV insulin. The full glucose lowering effect may not be apparent for at least 5 days <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml> and <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>]</content>.</paragraph>
                              <paragraph>To minimize the risk of hyperglycemia when initiating TOUJEO monitor glucose daily, titrate TOUJEO as described in this prescribing information, and adjust coadministered glucose-lowering therapies per standard of care <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2</linkHtml>, <linkHtml href="#S2.3">2.3)</linkHtml>]</content>. 										</paragraph>
                           </text>
                           <effectiveTime value="20240831"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="86796d2e-9ab7-4ae9-998e-41dd9784dfc4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3	Hypoglycemia</title>
                     <text>
                        <paragraph>Hypoglycemia is the most common adverse reaction associated with insulin, including TOUJEO. Severe hypoglycemia can cause seizures, may be life-threatening, or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place the patient and others at risk in situations where these abilities are important (e.g., driving, or operating other machinery). Hypoglycemia can happen suddenly, and symptoms may differ in each patient and change over time in the same patient. Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes, in patients with diabetic neuropathy, in patients using drugs that block the sympathetic nervous system (e.g., beta-blockers) <content styleCode="italics">[see <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>, or who experience recurrent hypoglycemia.</paragraph>
                        <paragraph>The long-acting effect of TOUJEO may delay recovery from hypoglycemia compared to shorter-acting insulins.</paragraph>
                     </text>
                     <effectiveTime value="20240831"/>
                     <component>
                        <section>
                           <id root="3349e379-45d7-49ab-aa2b-beca5e54caa3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Factors for Hypoglycemia</content>
                              </paragraph>
                              <paragraph>The timing of hypoglycemia usually reflects the time-action profile of the administered insulin formulation. As with all insulins, the glucose lowering effect time course of TOUJEO may vary in different patients or at different times in the same patient and depends on many conditions, including the area of injection as well as the injection site blood supply and temperature <content styleCode="italics">[see <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>]</content>. Other factors which may increase the risk of hypoglycemia include changes in meal pattern (e.g., macronutrient content or timing of meals), changes in level of physical activity, or changes to concomitant drugs <content styleCode="italics">[see <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>. Patients with renal or hepatic impairment may be at higher risk of hypoglycemia <content styleCode="italics">[see <linkHtml href="#S8.6">Use in Specific Populations (8.6</linkHtml>, <linkHtml href="#S8.7">8.7)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20240831"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="4b367597-8f86-42e2-bf2d-bfac510d21ec"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Mitigation Strategies for Hypoglycemia</content>
                              </paragraph>
                              <paragraph>Patients and caregivers must be educated to recognize and manage hypoglycemia. Self-monitoring of blood glucose plays an essential role in the prevention and management of hypoglycemia. In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of blood glucose monitoring is recommended. To minimize the risk of hypoglycemia, do not administer TOUJEO intravenously, intramuscularly or in an insulin pump, or dilute or mix TOUJEO with any other insulin products or solutions.</paragraph>
                           </text>
                           <effectiveTime value="20240831"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="783fba66-6408-47bc-ab4e-d169a265c2f4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4	Hypoglycemia Due to Medication Errors</title>
                     <text>
                        <paragraph>Accidental mix-ups between insulin products have been reported. To avoid medication errors between TOUJEO and other insulins, instruct patients to always check the insulin label before each injection.</paragraph>
                        <paragraph>To avoid dosing errors and potential overdose, never use a syringe to remove TOUJEO from the TOUJEO SoloStar or TOUJEO Max SoloStar prefilled pen into a syringe <content styleCode="italics">[see <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml> and <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>. 								</paragraph>
                     </text>
                     <effectiveTime value="20240831"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="361cebb6-9998-4c95-834d-1c34a6391655"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5	Hypersensitivity Reactions</title>
                     <text>
                        <paragraph>Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulins, including TOUJEO. If hypersensitivity reactions occur, discontinue TOUJEO; treat per standard of care and monitor until symptoms and signs resolve <content styleCode="italics">[see <linkHtml href="#S6">Adverse Reactions (6)</linkHtml>]</content>. TOUJEO is contraindicated in patients who have had hypersensitivity reactions to insulin glargine or any of the excipients in TOUJEO.</paragraph>
                     </text>
                     <effectiveTime value="20240831"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.6">
                     <id root="f87acd17-1249-4a7b-b1b0-d4d976714bae"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6	Hypokalemia</title>
                     <text>
                        <paragraph>All insulins, including TOUJEO, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia, if indicated (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations).</paragraph>
                     </text>
                     <effectiveTime value="20240831"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.7">
                     <id root="dae34dc7-1756-4349-a3c8-b92efd96dfc9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7	Fluid Retention and Heart Failure with Concomitant Use of PPAR-gamma Agonists</title>
                     <text>
                        <paragraph>Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose-related fluid retention, when used in combination with insulin. Fluid retention may lead to or exacerbate heart failure. Patients treated with insulin, including TOUJEO, and a PPAR-gamma agonist should be observed for signs and symptoms of heart failure. If heart failure develops, it should be managed according to current standards of care, and discontinuation or dose reduction of the PPAR-gamma agonist must be considered.</paragraph>
                     </text>
                     <effectiveTime value="20240831"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="e8fb8f8f-1cad-43ce-9eaa-3e81f2cc7956"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions are discussed elsewhere:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>Hypoglycemia <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                     <item>Hypoglycemia due to medication errors <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>
                     </item>
                     <item>Hypersensitivity Reactions <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>
                     </item>
                     <item>Hypokalemia <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20240831"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Adverse reactions commonly associated with TOUJEO (≥5%) are:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Hypoglycemia, allergic reactions, injection site reaction, lipodystrophy, pruritus, rash, edema, and weight gain. (<linkHtml href="#S6.1">6.1</linkHtml>, <linkHtml href="#S6.2">6.2</linkHtml>)</item>
                        </list>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact sanofi-aventis at 1-800-633-1610 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="b45d6126-889c-499e-95c5-d21cb8de6766"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1	Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates actually observed in clinical practice.</paragraph>
                        <paragraph>The data in Table 1 reflect the exposure of 304 patients with type 1 diabetes to TOUJEO with mean exposure duration of 23 weeks. The type 1 diabetes population had the following characteristics: Mean age was 46 years and mean duration of diabetes was 21 years. Fifty-five percent were male, 86% were White, 5% were Black or African American, and 5% were Hispanic or Latino. At baseline, the mean eGFR was 82 mL/min/1.73 m<sup>2</sup> and 35% of patients had eGFR ≥90 mL/min/1.73 m<sup>2</sup>. The mean body mass index (BMI) was 28 kg/m<sup>2</sup>. HbA1c at baseline was greater than or equal to 8% in 58% of patients.</paragraph>
                        <paragraph>The data in Table 2 reflect the exposure of 1242 patients with type 2 diabetes to TOUJEO with mean exposure duration of 25 weeks. The type 2 diabetes population had the following characteristics: Mean age was 59 years and mean duration of diabetes was 13 years. Fifty-three percent were male, 88% were White, 7% were Black or African American, and 17% were Hispanic or Latino. At baseline, mean eGFR was 79 mL/min/1.73 m<sup>2</sup> and 27% of patients had an eGFR ≥90 mL/min/1.73 m<sup>2</sup>. The mean BMI was 35 kg/m<sup>2</sup>. HbA1c at baseline was greater than or equal to 8% in 66% of patients.</paragraph>
                        <paragraph>TOUJEO was studied in 233 pediatric patients (6–17 years of age) with type 1 diabetes for a mean duration of 26 weeks <content styleCode="italics">[see <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>]</content>. 								</paragraph>
                        <paragraph>Common adverse reactions (occurring ≥5%) in TOUJEO-treated subjects during clinical trials in adult patients with type 1 diabetes mellitus and type 2 diabetes mellitus are listed in Table 1 and Table 2, respectively. Common adverse reactions for TOUJEO-treated pediatric subjects with type 1 diabetes mellitus were similar to the adverse reactions listed in Table 1. Hypoglycemia is discussed in a dedicated subsection below.</paragraph>
                        <table width="65%">
                           <caption>Table 1: Adverse Reactions Occurring ≥5% in Two Pooled Clinical Trials of 26 Weeks and 16 Weeks Duration in Adults with Type 1 Diabetes</caption>
                           <col width="45%" align="left" valign="middle"/>
                           <col width="55%" align="center" valign="middle"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">TOUJEO + Mealtime Insulin<footnote>"mealtime insulin" refers to insulin glulisine, insulin lispro, or insulin aspart.</footnote>, %<br/>(n=304)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Nasopharyngitis</td>
                                 <td styleCode="Rrule">12.8</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Upper respiratory tract infection</td>
                                 <td styleCode="Rrule">9.5</td>
                              </tr>
                           </tbody>
                        </table>
                        <table width="65%">
                           <caption>Table 2: Adverse Reactions Occurring ≥5% in Three Pooled Clinical Trials of 26 Weeks Duration in Adults with Type 2 Diabetes</caption>
                           <col width="45%" align="left" valign="middle"/>
                           <col width="55%" align="center" valign="middle"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">TOUJEO<footnote>one of the trials in type 2 diabetes included mealtime insulin.</footnote>, %<br/>(n=1242)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Nasopharyngitis</td>
                                 <td styleCode="Rrule">7.1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Upper respiratory tract infection</td>
                                 <td styleCode="Rrule">5.7</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240831"/>
                     <component>
                        <section>
                           <id root="38cf9c36-0bc9-4255-84c3-1d8ebaf6293e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Hypoglycemia</content>
                              </paragraph>
                              <paragraph>Hypoglycemia is the most commonly observed adverse reaction in patients treated with TOUJEO. The rates of reported hypoglycemia depend on the definition of hypoglycemia used, diabetes type, insulin dose, intensity of glucose control, background therapies, and other intrinsic and extrinsic patient factors. For these reasons, comparing rates of hypoglycemia in clinical trials for TOUJEO with the incidence of hypoglycemia for other products may be misleading and also may not be representative of hypoglycemia rates that will occur in clinical practice.</paragraph>
                              <paragraph>In the TOUJEO adult program, severe hypoglycemia was defined as an event requiring assistance of another person to administer a resuscitative action. In the pediatric program, severe hypoglycemia was defined as an event with semiconsciousness, unconsciousness, coma and/or convulsions in a patient who had altered mental status and could not assist in his own care, and who may have required glucagon or intravenous glucose.</paragraph>
                              <paragraph>The incidence of severe hypoglycemia in adult patients with type 1 diabetes receiving TOUJEO as part of a multiple daily injection regimen was 6.6% at 26 weeks. The incidence of hypoglycemia with a glucose level less than 54 mg/dL with or without symptoms was 77.7% at 26 weeks.</paragraph>
                              <paragraph>The incidence of severe hypoglycemia in pediatric patients with type 1 diabetes receiving TOUJEO as part of a multiple daily injection regimen was 6% at 26 weeks and the incidence of hypoglycemia accompanied by a self-monitored or plasma glucose value less than 54 mg/dL regardless of symptoms was 80.3%.</paragraph>
                              <paragraph>The incidence of severe hypoglycemia in adult patients with type 2 diabetes was 5% at 26 weeks in patients receiving TOUJEO as part of a multiple daily injection regimen, and 1.0% and 0.9% respectively at 26 weeks in the two studies where patients received TOUJEO as part of a basal-insulin only regimen. The incidence of hypoglycemia accompanied by a self-monitored or plasma glucose value less than 54 mg/dL regardless of symptoms in patients with type 2 diabetes receiving TOUJEO ranged from 9% to 44.6% at 26 weeks and the highest risk was again seen in patients receiving TOUJEO as part of a multiple daily injection regimen.</paragraph>
                           </text>
                           <effectiveTime value="20240831"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2354f3eb-69a4-4a34-8da7-59e95431f135"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Insulin Initiation and Intensification of Glucose Control </content>
                              </paragraph>
                              <paragraph>Intensification or rapid improvement in glucose control has been associated with a transitory, reversible ophthalmologic refraction disorder, worsening of diabetic retinopathy, and acute painful peripheral neuropathy. However, long-term glycemic control decreases the risk of diabetic retinopathy and neuropathy.</paragraph>
                           </text>
                           <effectiveTime value="20240831"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="b143fc98-47c0-43e9-ae3f-a2ed4bce394c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Peripheral Edema</content>
                              </paragraph>
                              <paragraph>Insulin, including TOUJEO, may cause sodium retention and edema, particularly if previously poor metabolic control was improved by intensified insulin therapy.</paragraph>
                           </text>
                           <effectiveTime value="20240831"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="047ac9fe-7f63-43ac-8cba-26598dc597bb"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Lipodystrophy</content>
                              </paragraph>
                              <paragraph>Long-term use of insulin, including TOUJEO, can cause lipoatrophy (depression in the skin) or lipohypertrophy (enlargement or thickening of tissue) in some patients and may affect insulin absorption <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>]</content>. 										</paragraph>
                           </text>
                           <effectiveTime value="20240831"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="9fbcbd17-aa2f-4904-8b48-1e7a5b3bf2a2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Weight Gain</content>
                              </paragraph>
                              <paragraph>Weight gain has occurred with insulins, including TOUJEO and has been attributed to the anabolic effects of insulin and the decrease in glucosuria.</paragraph>
                           </text>
                           <effectiveTime value="20240831"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="78805b41-e5c7-4055-ad68-84beb7959325"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Hypersensitivity Reactions</content>
                              </paragraph>
                              <paragraph>Patients taking TOUJEO experienced erythema, local edema, and pruritus at the site of injection. These conditions were usually self-limiting. </paragraph>
                              <paragraph>Severe cases of generalized allergy (anaphylaxis) have been reported.</paragraph>
                           </text>
                           <effectiveTime value="20240831"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="1640fb70-3592-410f-902c-be8c0d078e1e"/>
                     <code code="88830-5" codeSystem="2.16.840.1.113883.6.1" displayName="IMMUNOGENICITY"/>
                     <title>6.2	Immunogenicity</title>
                     <text>
                        <paragraph>As with all therapeutic proteins, there is potential for immunogenicity.</paragraph>
                        <paragraph>In a 6-month study of type 1 diabetes patients, 79% of patients who received TOUJEO once daily were positive for anti-insulin antibodies (AIA) at least once during the study, including 62% that were positive at baseline and 44% of patients who developed antidrug antibody (i.e., anti-insulin glargine antibody [ADA]) during the study. Eighty percent of the AIA-positive patients on TOUJEO with antibody test at baseline remained AIA positive at month 6.</paragraph>
                        <paragraph>In two 6-month studies in type 2 diabetes patients, 25% of patients who received TOUJEO once daily were positive for AIA at least once during the study, including 42% who were positive at baseline and 20% of patients who developed ADA during the study. Ninety percent of the AIA-positive patients on TOUJEO with antibody test at baseline, remained AIA positive at month 6.</paragraph>
                        <paragraph>The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay and may be influenced by several factors such as: assay methodology, sample handling, timing of sample collection, concomitant medication, and underlying disease. For these reasons, comparison of the incidence of antibodies to TOUJEO with the incidence of antibodies in other studies or to other products may be misleading.</paragraph>
                     </text>
                     <effectiveTime value="20240831"/>
                  </section>
               </component>
               <component>
                  <section ID="S6.3">
                     <id root="0b749e82-0c2f-461b-9bf4-a68d4d69dd65"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.3	Postmarketing Experience</title>
                     <text>
                        <paragraph>The following additional adverse reactions have been identified during postapproval use of TOUJEO. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>Localized cutaneous amyloidosis at the injection site has occurred. Hyperglycemia has been reported with repeated insulin injections into areas of localized cutaneous amyloidosis; hypoglycemia has been reported with a sudden change to an unaffected injection site.</paragraph>
                     </text>
                     <effectiveTime value="20240831"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="60391f7b-31f8-4404-8989-9bb841632b9f"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph>Table 3 includes clinically significant drug interactions with TOUJEO.</paragraph>
                  <table width="75%">
                     <caption>Table 3: Clinically Significant Drug Interactions with TOUJEO</caption>
                     <col width="20%" align="left" valign="middle"/>
                     <col width="80%" align="left" valign="middle"/>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">Drugs That May Increase the Risk of Hypoglycemia</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Drugs:</content>
                           </td>
                           <td styleCode="Rrule">Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Rrule">Dosage reductions and increased frequency of glucose monitoring may be required when TOUJEO is coadministered with these drugs.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">Drugs That May Decrease the Blood Glucose Lowering Effect of TOUJEO</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Drugs:</content>
                           </td>
                           <td styleCode="Rrule">Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Rrule">Dosage increases and increased frequency of glucose monitoring may be required when TOUJEO is coadministered with these drugs.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of TOUJEO</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Drugs:</content>
                           </td>
                           <td styleCode="Rrule">Alcohol, beta-blockers, clonidine, and lithium salts. Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Rrule">Dosage adjustment and increased frequency of glucose monitoring may be required when TOUJEO is coadministered with these drugs.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">Drugs That May Blunt Signs and Symptoms of Hypoglycemia </content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Drugs:</content>
                           </td>
                           <td styleCode="Rrule">Beta-blockers, clonidine, guanethidine, and reserpine.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Rrule">Increased frequency of glucose monitoring may be required when TOUJEO is coadministered with these drugs.</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20240831"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="italics">Drugs that Affect Glucose Metabolism:</content> Adjustment of insulin dosage may be needed. (<linkHtml href="#S7">7</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Antiadrenergic Drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine):</content> Signs and symptoms of hypoglycemia may be reduced or absent. (<linkHtml href="#S5.3">5.3</linkHtml>, <linkHtml href="#S7">7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="2821c8fd-f884-4954-ba1f-595a37115e5d"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20240831"/>
               <component>
                  <section ID="S8.1">
                     <id root="f89dc3b7-a3b3-4777-8d73-6d83cf9fb1f3"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20240831"/>
                     <component>
                        <section>
                           <id root="f8d534c7-0d29-41d6-80a5-7be2056a33bd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Published studies with use of insulin glargine during pregnancy have not reported a clear association with insulin glargine and adverse developmental outcomes <content styleCode="italics">(see <linkHtml href="#data">Data</linkHtml>)</content>. There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy <content styleCode="italics">(see <linkHtml href="#clinicalconsiderations">Clinical Considerations</linkHtml>)</content>.</paragraph>
                              <paragraph>Rats and rabbits were exposed to insulin glargine in animal reproduction studies during organogenesis, respectively 50 times and 10 times the human subcutaneous dose of 0.2 unit/kg/day. Overall, the effects of insulin glargine did not generally differ from those observed with regular human insulin <content styleCode="italics">(see <linkHtml href="#data">Data</linkHtml>)</content>.</paragraph>
                              <paragraph>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. The estimated background risk of major birth defects is 6% to 10% in women with pregestational diabetes with a peri-conceptional HbA1c &gt;7 and has been reported to be as high as 20% to 25% in women with a peri-conceptional HbA1c &gt;10. The estimated background risk of miscarriage for the indicated population is unknown. </paragraph>
                           </text>
                           <effectiveTime value="20240831"/>
                        </section>
                     </component>
                     <component>
                        <section ID="clinicalconsiderations">
                           <id root="e50db3f1-56e6-4f55-ac92-cd78955fc9c6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20240831"/>
                           <component>
                              <section>
                                 <id root="9f28c1c3-3b19-4978-8100-59147e443a7a"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>Disease-Associated Maternal and/or Embryo/fetal Risk</paragraph>
                                    <paragraph>Hypoglycemia and hyperglycemia occur more frequently during pregnancy in patients with pre-gestational diabetes. Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, preeclampsia, spontaneous abortions, preterm delivery, and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia-related morbidity.</paragraph>
                                 </text>
                                 <effectiveTime value="20240831"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="data">
                           <id root="08389967-b407-4c30-9e93-39bad1c6bd9d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20240831"/>
                           <component>
                              <section>
                                 <id root="f82e632f-4cdb-48cf-8393-8653e655ba89"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>Human Data</paragraph>
                                    <paragraph>Published data do not report a clear association with insulin glargine and major birth defects, miscarriage, or adverse maternal or fetal outcomes when insulin glargine is used during pregnancy. However, these studies cannot definitely establish the absence of any risk because of methodological limitations including small sample size and some lacking comparator groups.</paragraph>
                                 </text>
                                 <effectiveTime value="20240831"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="b5057683-3a74-475f-b862-e16886e8397d"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>Animal Data</paragraph>
                                    <paragraph>Subcutaneous reproduction and teratology studies have been performed with insulin glargine and regular human insulin in rats and Himalayan rabbits. Insulin glargine was given to female rats before mating, during mating, and throughout pregnancy at doses up to 0.36 mg/kg/day, which is approximately 50 times the recommended human subcutaneous starting dosage of 0.2 Units/kg/day (0.007 mg/kg/day). In rabbits, doses of 0.072 mg/kg/day, which is approximately 10 times the recommended human subcutaneous starting dosage of 0.2 Units/kg/day (0.007 mg/kg/day), were administered during organogenesis. The effects of insulin glargine did not generally differ from those observed with regular human insulin in rats or rabbits. However, in rabbits, five fetuses from two litters of the high-dose group exhibited dilation of the cerebral ventricles. Fertility and early embryonic development appeared normal.</paragraph>
                                 </text>
                                 <effectiveTime value="20240831"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="6fb66a11-356c-470f-bf70-785992641f8c"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2	Lactation</title>
                     <effectiveTime value="20240831"/>
                     <component>
                        <section>
                           <id root="e60d7f72-83e4-4bba-94d4-07db8b0b62e1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are either no or only limited data on the presence of insulin glargine in human milk, the effects on breastfed infant, or the effects on milk production. Endogenous insulin is present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for TOUJEO, and any potential adverse effects on the breastfed child from TOUJEO or from the underlying maternal condition.</paragraph>
                           </text>
                           <effectiveTime value="20240831"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="f57f56d6-7e68-4ee6-b2e3-124b3b695c50"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of TOUJEO to improve glycemic control in pediatric patients 6 years of age and older with diabetes mellitus have been established.</paragraph>
                        <paragraph>The use of TOUJEO for this indication is supported by evidence from an adequate and well-controlled study in 463 pediatric patients 6 to 17 years of age with type 1 diabetes mellitus <content styleCode="italics">[see <linkHtml href="#S14.2">Clinical Studies (14.2)</linkHtml>]</content> and from studies in adults with diabetes mellitus <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>, <linkHtml href="#S14.3">Clinical Studies (14.3)</linkHtml>]</content>.</paragraph>
                        <paragraph>The safety and effectiveness of TOUJEO have not been established in pediatric patients less than 6 years of age.</paragraph>
                     </text>
                     <effectiveTime value="20240831"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="4a174bc6-664d-4211-a4f9-4629d39d12db"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>In controlled clinical studies, 30 of 304 (9.8%) TOUJEO-treated patients with type 1 diabetes and 327 of 1242 (26.3%) TOUJEO-treated patients with type 2 diabetes were ≥65 years of age, among them 2.0% of the patients with type 1 and 3.0% of the patients with type 2 diabetes were ≥75 years of age. No overall differences in safety or effectiveness of TOUJEO have been observed between patients 65 years of age and older and younger adult patients.</paragraph>
                        <paragraph>Nevertheless, caution should be exercised when TOUJEO is administered to geriatric patients. In geriatric patients with diabetes, the initial dosing, dose increments, and maintenance dosage should be conservative to avoid hypoglycemia <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>, <linkHtml href="#S6">Adverse Reactions (6)</linkHtml>, and <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>. 								</paragraph>
                     </text>
                     <effectiveTime value="20240831"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="cdb854a8-3a1a-44e5-b6c7-7be8bf1c0950"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.6	Renal Impairment</title>
                     <text>
                        <paragraph>The effect of kidney impairment on the pharmacokinetics of TOUJEO has not been studied. Some studies with human insulin have shown increased circulating levels of insulin in patients with kidney failure. Frequent glucose monitoring and dose adjustment may be necessary for TOUJEO in patients with kidney impairment <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240831"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.7">
                     <id root="0d884a34-fc62-4c2a-b32a-43107bdf8909"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.7	Hepatic Impairment</title>
                     <text>
                        <paragraph>The effect of hepatic impairment on the pharmacokinetics of TOUJEO has not been studied. Frequent glucose monitoring and dose adjustment may be necessary for TOUJEO in patients with hepatic impairment <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240831"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="19f6c76e-bf40-409e-946e-6f3339cf1a55"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Excess insulin administration may cause hypoglycemia and hypokalemia <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3</linkHtml>, <linkHtml href="#S5.6">5.6)</linkHtml>]</content>. Mild episodes of hypoglycemia can be treated with oral glucose. Lowering the insulin dosage, and adjustments in meal patterns, or physical activity level may be needed. More severe episodes of hypoglycemia with coma, seizure, or neurologic impairment may be treated with glucagon for emergency use or concentrated intravenous glucose. Sustained carbohydrate intake and observation may be necessary because hypoglycemia may recur after apparent clinical recovery. Hypokalemia must be corrected appropriately.</paragraph>
               </text>
               <effectiveTime value="20240831"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="b23e16d4-b4a5-45d9-9fcc-b3091010580f"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Insulin glargine is a long-acting human insulin analog produced by recombinant DNA technology utilizing a nonpathogenic laboratory strain of <content styleCode="italics">Escherichia coli</content> (K12) as the production organism. Insulin glargine differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and two arginines remain at the C-terminus of the B-chain. Insulin glargine has a molecular weight of 6063 Da.</paragraph>
                  <paragraph>TOUJEO (insulin glargine) injection is a sterile, clear and colorless solution for subcutaneous injection. Each mL of TOUJEO contains 300 units of insulin glargine dissolved in a clear aqueous fluid.</paragraph>
                  <paragraph>The 1.5 mL TOUJEO SoloStar prefilled pen presentation contains the following inactive ingredients per mL: glycerin (20 mg), metacresol (2.7 mg), zinc (90 mcg), and Water for Injection, USP.</paragraph>
                  <paragraph>The 3 mL TOUJEO Max SoloStar prefilled pen presentation contains the following inactive ingredients per mL: glycerin (20 mg), metacresol (2.7 mg), zinc (90 mcg), and Water for Injection, USP.</paragraph>
                  <paragraph>The pH is adjusted by addition of aqueous solutions of hydrochloric acid and sodium hydroxide. TOUJEO has a pH of approximately 4.</paragraph>
               </text>
               <effectiveTime value="20240831"/>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="41db4d74-b6d9-4e76-a0e5-30d7794febb5"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20240831"/>
               <component>
                  <section ID="S12.1">
                     <id root="54e7bbf9-c2af-43c9-90c6-3fdd1d59349c"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis and enhances protein synthesis.</paragraph>
                     </text>
                     <effectiveTime value="20240831"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="2b481ae7-a5ad-4edd-ba9f-0b27b79bba65"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <effectiveTime value="20240831"/>
                     <component>
                        <section>
                           <id root="67c7763f-51e1-47da-9cbe-62fee792eb49"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Onset of Action</content>
                              </paragraph>
                              <paragraph>The pharmacodynamic profiles for TOUJEO given subcutaneously as a single dose of 0.4, 0.6, or 0.9 U/kg in a euglycemic clamp study in patients with type 1 diabetes showed that on average, the onset of action develops over 6 hours post dose for all three single doses of TOUJEO.</paragraph>
                           </text>
                           <effectiveTime value="20240831"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="dfc99609-6002-4fa9-85d5-2bd44f97f918"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Single-Dose Pharmacodynamics</content>
                              </paragraph>
                              <paragraph>The pharmacodynamics for single 0.4, 0.6, and 0.9 U/kg doses of TOUJEO in 24 patients with type 1 diabetes mellitus was evaluated in a euglycemic clamp study. On a unit-to-unit basis, TOUJEO had a lower maximum (GIR<sub>max</sub>) and 24-hour glucose lowering effect (GIR-AUC<sub>0–24</sub>) compared to LANTUS. The overall glucose lowering effect of TOUJEO 0.4 U/kg was 12% of the glucose lowering effect of an equivalent dose of LANTUS. Glucose lowering at least 30% of the effect of a single 0.4 U/kg dose of LANTUS was not observed until the single dose of TOUJEO exceeded 0.6 U/kg.</paragraph>
                           </text>
                           <effectiveTime value="20240831"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="45e89698-301d-461d-9b52-8f004ee0c684"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Multiple Once-Daily Dose Pharmacodynamics</content>
                              </paragraph>
                              <paragraph>The pharmacodynamics of TOUJEO after 8 days of daily injection was evaluated in 30 patients with type 1 diabetes. At steady state, the 24-hour glucose lowering effect (GIR-AUC<sub>0–24</sub>) of TOUJEO 0.4 U/kg was approximately 27% lower with a different distribution profile than that of an equivalent dose of LANTUS <content styleCode="italics">[see <linkHtml href="#S2">Dosage and Administration (2)</linkHtml>, <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>, and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. The glucose lowering effect of a TOUJEO dose increased with each daily administration.</paragraph>
                              <paragraph>The pharmacodynamic profile for TOUJEO given subcutaneously as multiple once-daily subcutaneous injections of 0.4 U/kg in a euglycemic clamp study in patients with type 1 diabetes is shown in Figure 1.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Figure 1: Glucose Infusion Rate in Patients with Type 1 Diabetes in Multiple-Dose Administration of TOUJEO</content>
                              </paragraph>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM1"/>
                              </paragraph>
                              <paragraph>Glucose infusion rate: determined as amount of glucose infused to maintain constant plasma glucose levels.</paragraph>
                           </text>
                           <effectiveTime value="20240831"/>
                           <component>
                              <observationMedia ID="MM1">
                                 <text>Figure 1</text>
                                 <value xsi:type="ED" mediaType="image/jpeg">
                                    <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-01.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="06857733-6e89-47e2-aed4-d4967352f441"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <effectiveTime value="20240831"/>
                     <component>
                        <section>
                           <id root="9ca7c659-5be2-4a60-85bf-c9bacbc43736"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                              <paragraph>The pharmacokinetic profiles for single 0.4, 0.6, and 0.9 U/kg doses of TOUJEO in 24 patients with type 1 diabetes mellitus was evaluated in a euglycemic clamp study. The median time to maximum serum insulin concentration was 12 (8–14), 12 (12–18), and 16 (12–20) hours, respectively. Mean serum insulin concentrations declined to the lower limit of quantitation of 5.02 µU/mL by 16, 28, and beyond 36 hours, respectively.</paragraph>
                              <paragraph>Steady-state insulin concentrations are reached by at least 5 days of once-daily subcutaneous administration of 0.4 U/kg to 0.6 U/kg doses of TOUJEO over 8 days in patients with type 1 diabetes mellitus.</paragraph>
                              <paragraph>After subcutaneous injection of TOUJEO, the intra-subject variability, defined as the coefficient of variation for the insulin exposure during 24 hours, was 21.0% at steady state.</paragraph>
                           </text>
                           <effectiveTime value="20240831"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="ae4aee11-2131-4e43-b01b-c13dbd4af9a6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>After subcutaneous injection of TOUJEO in diabetic patients, insulin glargine is metabolized at the carboxyl terminus of the B-chain with formation of two active metabolites M1 (21<sup>A</sup>-Gly-insulin) and M2 (21<sup>A</sup>-Gly-des-30<sup>B</sup>-Thr-insulin). The <content styleCode="italics">in vitro</content> activity of M1 and M2 were similar to that of human insulin.</paragraph>
                           </text>
                           <effectiveTime value="20240831"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="51845bf0-290f-4c52-b74c-81285f07d1ed"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20240831"/>
                           <component>
                              <section>
                                 <id root="fdf9bd9a-7be0-4530-9250-bf25c958042d"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Pediatrics</content>
                                    </paragraph>
                                    <paragraph>Population pharmacokinetic analysis was conducted for TOUJEO based on concentration data of its main metabolite M1 using data from 75 pediatric patients (6 to &lt;18 years of age) with type 1 diabetes. The findings with regard to the effect of body weight on systemic exposure of M1 are generally consistent with findings in adults.</paragraph>
                                 </text>
                                 <effectiveTime value="20240831"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="440af959-2ff2-41d4-b7b6-43496b33c7d5"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Elderly, Race, Sex, and Obesity</content>
                                    </paragraph>
                                    <paragraph>Effect of age ≥65, race, and sex on the pharmacokinetics of TOUJEO has not been evaluated. When weight is taken into account as a covariate on clearance, BMI is not an additional covariate.</paragraph>
                                 </text>
                                 <effectiveTime value="20240831"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="3c3ca038-d155-454f-97fc-8124503d43b6"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20240831"/>
               <component>
                  <section ID="S13.1">
                     <id root="b114e8d9-f79c-44c9-b854-0804dd49e356"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>In mice and rats, standard two-year carcinogenicity studies with insulin glargine were performed at doses up to 0.455 mg/kg, which was for the rat approximately 65 times the recommended human subcutaneous starting dosage of 0.2 Units/kg/day (0.007 mg/kg/day). The findings in female mice were not conclusive due to excessive mortality in all dose groups during the study. Histiocytomas were found at injection sites in male rats (statistically significant) and male mice (not statistically significant) in acid vehicle containing groups. These tumors were not found in female animals, in saline control, or insulin comparator groups using a different vehicle. The relevance of these findings to humans is unknown.</paragraph>
                        <paragraph>Insulin glargine was not mutagenic in tests for detection of gene mutations in bacteria and mammalian cells (Ames and HGPRT test) and in tests for detection of chromosomal aberrations (cytogenetics <content styleCode="italics">in vitro</content> in V79 cells and <content styleCode="italics">in vivo</content> in Chinese hamsters).</paragraph>
                        <paragraph>In a combined fertility and prenatal and postnatal study in male and female rats at subcutaneous doses up to 0.36 mg/kg/day, which was approximately 50 times the recommended human subcutaneous starting dose of 0.2 Units/kg/day (0.007 mg/kg/day), maternal toxicity due to dose-dependent hypoglycemia, including some deaths, was observed. Consequently, a reduction of the rearing rate occurred in the high-dose group only. Similar effects were observed with NPH insulin.</paragraph>
                     </text>
                     <effectiveTime value="20240831"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="f5994b28-070d-4bd5-9f20-e50e23e4fbbc"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20240831"/>
               <component>
                  <section ID="S14.1">
                     <id root="aff81ccd-624c-4713-b3d7-84d0c06d5a14"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Overview of Clinical Studies</title>
                     <text>
                        <paragraph>The efficacy of TOUJEO given once daily was compared to that of once-daily LANTUS in 26-week, open-label, randomized, active-control, parallel studies of 546 adult patients and 463 pediatric patients with type 1 diabetes mellitus and 2,474 patients with type 2 diabetes mellitus (Tables 4 and 5). At trial end, the reduction in glycated hemoglobin (HbA1c) and fasting plasma glucose with TOUJEO titrated to goal was similar to that with LANTUS titrated to goal. At the end of the trial, depending on the patient population and concomitant therapy, patients were receiving a higher dose of TOUJEO than LANTUS.</paragraph>
                     </text>
                     <effectiveTime value="20240831"/>
                  </section>
               </component>
               <component>
                  <section ID="S14.2">
                     <id root="097a0ae8-bcb3-4963-a6b3-e62e4c38e3c8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 Clinical Study in Adult and Pediatric Patients with Type 1 Diabetes</title>
                     <effectiveTime value="20240831"/>
                     <component>
                        <section>
                           <id root="57d0d50b-98e3-4640-b117-0582a96725e6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adult Patients with Type 1 Diabetes </content>
                              </paragraph>
                              <paragraph>In an open-label, controlled study (Study A), patients with type 1 diabetes (n=546), were randomized to basal-bolus treatment with TOUJEO or LANTUS and treated for 26 weeks. TOUJEO and LANTUS were administered once daily in the morning (time period covering from pre-breakfast until pre-lunch) or in the evening (time period defined as prior to the evening meal until at bedtime). A mealtime insulin analogue was administered before each meal. Mean age was 47 years and mean duration of diabetes was 21 years. Fifty-seven percent were male, 85% were White, 5% Black or African American, and 5% were Hispanic or Latino; 32% of patients had GFR &gt;90 mL/min/1.73 m<sup>2</sup>. The mean BMI was approximately 27.6 kg/m<sup>2</sup>. At week 26, treatment with TOUJEO provided a mean reduction in HbA1c that met the prespecified noninferiority margin of 0.4% (Table 4). Patients treated with TOUJEO used 18% more basal insulin than patients treated with LANTUS. There were no clinically important differences in glycemic control when TOUJEO was administered once daily in the morning or in the evening. There were no clinically important differences in body weight between treatment groups.</paragraph>
                              <table width="75%">
                                 <caption>Table 4 : Type 1 Diabetes Mellitus – Adult Patients (TOUJEO plus mealtime insulin versus LANTUS plus mealtime insulin)</caption>
                                 <col width="54%" align="left" valign="middle"/>
                                 <col width="23%" align="center" valign="middle"/>
                                 <col width="23%" align="center" valign="middle"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule"/>
                                       <th>TOUJEO + Mealtime Insulin<footnote ID="t4ft1">"mealtime insulin" refers to insulin glulisine, insulin lispro or insulin aspart.</footnote>
                                       </th>
                                       <th styleCode="Rrule">LANTUS + Mealtime Insulin<footnoteRef IDREF="t4ft1"/>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Treatment duration</td>
                                       <td styleCode="Rrule" colspan="2">26 weeks</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Treatment in combination with</td>
                                       <td styleCode="Rrule" colspan="2">Fast-acting insulin analogue</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Number of subjects treated (mITT<footnote ID="t4ft2">mITT: Modified intention-to-treat population.</footnote>)</td>
                                       <td>273</td>
                                       <td styleCode="Rrule">273</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule">
                                          <content styleCode="bold">HbA1c (%)</content>
                                       </td>
                                       <td styleCode="Rrule" colspan="2"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Baseline mean</td>
                                       <td>8.13</td>
                                       <td styleCode="Rrule">8.12</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Adjusted mean change from baseline</td>
                                       <td>-0.40</td>
                                       <td styleCode="Rrule">-0.44</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Adjusted mean difference<footnote ID="t4ft3">Treatment difference: TOUJEO – LANTUS.</footnote>
                                          <br/>[95% Confidence Interval]</td>
                                       <td styleCode="Rrule" colspan="2">0.04<br/>[-0.10 to 0.18]</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule">
                                          <content styleCode="bold">Fasting Plasma Glucose mg/dL</content>
                                       </td>
                                       <td/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Baseline mean</td>
                                       <td>186</td>
                                       <td styleCode="Rrule">199</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Adjusted mean change from baseline</td>
                                       <td>-17</td>
                                       <td styleCode="Rrule">-20</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Adjusted mean difference<footnoteRef IDREF="t4ft3"/>
                                          <br/>[95% Confidence Interval]</td>
                                       <td styleCode="Rrule" colspan="2">3<br/>[-10 to 16]</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20240831"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="1cdfa283-3732-4ca2-ac2a-1c7be1d514b8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pediatric Patients with Type 1 Diabetes</content>
                              </paragraph>
                              <paragraph>The efficacy of TOUJEO was evaluated in a 26-week, randomized, open-label, multicenter trial (Study B) in 463 pediatric patients with type 1 diabetes mellitus. Patients were randomized to basal-bolus treatment with TOUJEO or LANTUS and treated for 26 weeks. TOUJEO and LANTUS were administered once daily in the morning or in the evening. A mealtime insulin analogue was administered before each meal.</paragraph>
                              <paragraph>The mean age of the trial population was 13 years; 31% were &lt;12 years of age, 69% were ages ≥12 years of age. The mean duration of diabetes was 6 years. Of the 463 pediatric patients, 51% were male, 92% were White, 3% were Black or African American, and 30% were Hispanic or Latino. The mean baseline BMI percentile was 68.32.</paragraph>
                              <paragraph>At week 26, the difference in HbA1c reduction from baseline between TOUJEO and LANTUS was 0.02% with a 95% confidence interval (-0.16%; 0.20%) and met the prespecified noninferiority margin (0.3%). The results are presented in Table 5.</paragraph>
                              <table width="75%">
                                 <caption>Table 5: Type 1 Diabetes Mellitus – Pediatric Patients at 26 weeks (TOUJEO plus mealtime insulin versus LANTUS plus mealtime insulin)</caption>
                                 <col width="54%" align="left" valign="middle"/>
                                 <col width="23%" align="center" valign="middle"/>
                                 <col width="23%" align="center" valign="middle"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule"/>
                                       <th>TOUJEO + Mealtime Insulin<footnote ID="tb5ft1">"mealtime insulin" refers to insulin glulisine, insulin lispro or insulin aspart.</footnote>
                                       </th>
                                       <th styleCode="Rrule">LANTUS + Mealtime Insulin<footnoteRef IDREF="tb5ft1"/>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Number of subjects (ITT<footnote>ITT: Intention-to-treat: all randomized subjects.</footnote>)</td>
                                       <td>233</td>
                                       <td styleCode="Rrule">230</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule">
                                          <content styleCode="bold">HbA1c (%)</content>
                                          <footnote ID="tb5ft2">At week 26, change in HbA1c was missing for 3.9% and 4.3% of subjects, and change in FPG was missing for 12.4% and 12.2% of subjects, in TOUJEO and LANTUS respectively. Missing values were imputed with return-to-baseline method for subjects who permanently discontinued the treatment.</footnote>
                                       </td>
                                       <td styleCode="Rrule" colspan="2"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Baseline mean</td>
                                       <td>8.65</td>
                                       <td styleCode="Rrule">8.61</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Adjusted Mean change from baseline</td>
                                       <td>-0.386</td>
                                       <td styleCode="Rrule">-0.404</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Adjusted Mean difference<footnote ID="tb5ft3">Treatment difference: TOUJEO – LANTUS.</footnote>
                                          <br/>[95% Confidence Interval]</td>
                                       <td styleCode="Rrule" colspan="2">0.018<br/> [-0.159, 0.195]</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule">
                                          <content styleCode="bold">Fasting Plasma Glucose (mg/dL)</content>
                                          <footnoteRef IDREF="tb5ft2"/>
                                       </td>
                                       <td/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Baseline mean</td>
                                       <td>202.70</td>
                                       <td styleCode="Rrule">204.51</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Adjusted Mean change from baseline</td>
                                       <td>-10.447</td>
                                       <td styleCode="Rrule">-10.633</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Adjusted Mean difference<footnoteRef IDREF="tb5ft3"/>
                                          <br/>[95% Confidence Interval]</td>
                                       <td styleCode="Rrule" colspan="2">0.185<br/>[-18.131, 18.501]</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20240831"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S14.3">
                     <id root="e12161f9-d52a-4174-bbc7-e619700aafcc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.3 Clinical Studies in Adult Patients with Type 2 Diabetes</title>
                     <text>
                        <paragraph>In a 26-week open-label, controlled study (Study C, n=804), adults with type 2 diabetes were randomized to once-daily treatment in the evening with either TOUJEO or LANTUS. Short-acting mealtime insulin analogues with or without metformin were also administered. The average age was 60 years. The majority of patients were White (92%) and 53% were male; 20% of patients had GFR &gt;90 mL/min/1.73 m<sup>2</sup>. The mean BMI was approximately 36.6 kg/m<sup>2</sup>. At week 26, treatment with TOUJEO provided a mean reduction in HbA1c that met the prespecified noninferiority margin of 0.4% compared to LANTUS (Table 6). Patients treated with TOUJEO used 11% more basal insulin than patients treated with LANTUS. There were no clinically important differences in body weight between treatment groups.</paragraph>
                        <paragraph>In two open-label, controlled studies (n=1670), adults with type 2 diabetes mellitus were randomized to either TOUJEO or LANTUS once daily for 26 weeks as part of a regimen of combination therapy with noninsulin antidiabetic drugs. At the time of randomization, 808 patients were treated with basal insulin for more than 6 months (Study D) and 862 patients were insulin-naive (Study E).</paragraph>
                        <paragraph>In Study D, the average age was 58.2 years. The majority of patients were White (94%) and 46% were male; 33% of patients had GFR &gt;90 mL/min/1.73 m<sup>2</sup>. The mean BMI was approximately 34.8 kg/m<sup>2</sup>. At week 26, treatment with TOUJEO provided a mean reduction in HbA1c that met the prespecified noninferiority margin of 0.4% compared to LANTUS (Table 6). Patients treated with TOUJEO used 12% more basal insulin than patients treated with LANTUS. There were no clinically important differences in body weight between treatment groups.</paragraph>
                        <paragraph>In Study E, the average age was 58 years. The majority of patients were White (78%) and 58% were male; 29% of patients had GFR &gt;90 mL/min/1.73 m<sup>2</sup>. The mean BMI was approximately 33 kg/m<sup>2</sup>. At week 26, treatment with TOUJEO provided a mean reduction in HbA1c that met the prespecified noninferiority margin compared to LANTUS (Table 6). Patients treated with TOUJEO used 15% more basal insulin than patients treated with LANTUS. There were no clinically important differences in body weight between treatment groups.</paragraph>
                        <table width="75%">
                           <caption>Table 6: Type 2 Diabetes Mellitus – Adult</caption>
                           <col width="19%" align="left" valign="top"/>
                           <col width="13%" align="center" valign="middle"/>
                           <col width="13%" align="center" valign="middle"/>
                           <col width="13%" align="center" valign="middle"/>
                           <col width="14%" align="center" valign="middle"/>
                           <col width="14%" align="center" valign="middle"/>
                           <col width="14%" align="center" valign="middle"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule" colspan="2">Study C</th>
                                 <th styleCode="Rrule" colspan="2">Study D</th>
                                 <th styleCode="Rrule" colspan="2">Study E</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Treatment duration</content>
                                 </td>
                                 <td styleCode="Rrule" colspan="2">26 weeks</td>
                                 <td styleCode="Rrule" colspan="2">26 weeks</td>
                                 <td styleCode="Rrule" colspan="2">26 weeks</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Treatment in combination with</content>
                                 </td>
                                 <td styleCode="Rrule" colspan="2">Mealtime insulin analog ± metformin</td>
                                 <td styleCode="Rrule" colspan="4">Noninsulin antidiabetic drugs</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule"/>
                                 <td styleCode="Rrule">TOUJEO</td>
                                 <td styleCode="Rrule">LANTUS</td>
                                 <td styleCode="Rrule">TOUJEO</td>
                                 <td styleCode="Rrule">LANTUS</td>
                                 <td styleCode="Rrule">TOUJEO</td>
                                 <td styleCode="Rrule">LANTUS</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Number of patients treated<footnote>m-ITT population: Modified intention-to-treat population.</footnote>
                                 </td>
                                 <td styleCode="Rrule">404</td>
                                 <td styleCode="Rrule">400</td>
                                 <td styleCode="Rrule">403</td>
                                 <td styleCode="Rrule">405</td>
                                 <td styleCode="Rrule">432</td>
                                 <td styleCode="Rrule">430</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">HbA1c (%)</content>
                                 </td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Baseline mean</td>
                                 <td styleCode="Rrule">8.13</td>
                                 <td styleCode="Rrule">8.14</td>
                                 <td styleCode="Rrule">8.27</td>
                                 <td styleCode="Rrule">8.22</td>
                                 <td styleCode="Rrule">8.49</td>
                                 <td styleCode="Rrule">8.58</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Adjusted mean change from baseline</td>
                                 <td styleCode="Rrule" valign="middle">-0.90</td>
                                 <td styleCode="Rrule" valign="middle">-0.87</td>
                                 <td styleCode="Rrule" valign="middle">-0.73</td>
                                 <td styleCode="Rrule" valign="middle">-0.70</td>
                                 <td styleCode="Rrule" valign="middle">-1.42</td>
                                 <td styleCode="Rrule" valign="middle">-1.46</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Adjusted mean difference<footnote ID="t5f2">Treatment difference: TOUJEO – LANTUS.</footnote>
                                 </td>
                                 <td styleCode="Rrule" colspan="2" valign="bottom">-0.03</td>
                                 <td styleCode="Rrule" colspan="2" valign="bottom">-0.03</td>
                                 <td styleCode="Rrule" colspan="2" valign="bottom">0.04</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">[95% Confidence interval]</td>
                                 <td styleCode="Rrule" colspan="2" valign="bottom">[-0.14 to 0.08]</td>
                                 <td styleCode="Rrule" colspan="2" valign="bottom">[-0.17 to 0.10]</td>
                                 <td styleCode="Rrule" colspan="2" valign="bottom">[-0.09 to 0.17]</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Fasting Plasma Glucose (mg/dL)</content>
                                 </td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Baseline mean</td>
                                 <td styleCode="Rrule">157</td>
                                 <td styleCode="Rrule">160</td>
                                 <td styleCode="Rrule">149</td>
                                 <td styleCode="Rrule">142</td>
                                 <td styleCode="Rrule">179</td>
                                 <td styleCode="Rrule">184</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Adjusted mean change from baseline</td>
                                 <td styleCode="Rrule" valign="middle">-29</td>
                                 <td styleCode="Rrule" valign="middle">-30</td>
                                 <td styleCode="Rrule" valign="middle">-18</td>
                                 <td styleCode="Rrule" valign="middle">-22</td>
                                 <td styleCode="Rrule" valign="middle">-61</td>
                                 <td styleCode="Rrule" valign="middle">-68</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Adjusted mean difference<footnoteRef IDREF="t5f2"/>
                                 </td>
                                 <td styleCode="Rrule" colspan="2" valign="bottom">0.8</td>
                                 <td styleCode="Rrule" colspan="2" valign="bottom">3</td>
                                 <td styleCode="Rrule" colspan="2" valign="bottom">7</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">[95% Confidence interval]</td>
                                 <td styleCode="Rrule" colspan="2" valign="bottom">[-5 to 7]</td>
                                 <td styleCode="Rrule" colspan="2" valign="bottom">[-3 to 9]</td>
                                 <td styleCode="Rrule" colspan="2" valign="bottom">[2 to 12]</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240831"/>
                     <component>
                        <section>
                           <id root="6c37ae80-fff9-4233-ac69-730845707007"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Safety Outcomes Trial</content>
                              </paragraph>
                              <paragraph>No clinical studies to establish the cardiovascular safety of TOUJEO have been conducted. A cardiovascular outcomes trial, ORIGIN, has been conducted with LANTUS. It is unknown whether the results of ORIGIN can be applied to TOUJEO.</paragraph>
                              <paragraph>The Outcome Reduction with Initial Glargine Intervention trial (i.e., ORIGIN) was an open-label, randomized, 12,537 patient study that compared LANTUS to standard care on the time to first occurrence of a major adverse cardiovascular event (MACE). MACE was defined as the composite of CV death, nonfatal myocardial infarction, and nonfatal stroke. The incidence of MACE was similar between LANTUS and standard care in ORIGIN (Hazard Ratio [95% CI] for MACE; 1.02 [0.94, 1.11]).</paragraph>
                              <paragraph>In the ORIGIN trial, the overall incidence of cancer (all types combined) (Hazard Ratio [95% CI]; 0.99 [0.88, 1.11]) or death from cancer (Hazard Ratio [95% CI]; 0.94 [0.77, 1.15]) was also similar between treatment groups.</paragraph>
                           </text>
                           <effectiveTime value="20240831"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="dc818312-a698-410b-bb3b-141b7e12ff4b"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20240831"/>
               <component>
                  <section ID="S16.1">
                     <id root="493658fb-8f73-4ee0-88c6-6ea1e2bc1829"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>16.1 How Supplied</title>
                     <text>
                        <paragraph>TOUJEO (insulin glargine) injection, 300 units/mL (U-300), is a clear and colorless solution and is available as:</paragraph>
                        <table width="75%">
                           <col width="15%" align="left" valign="middle"/>
                           <col width="14%" align="center" valign="middle"/>
                           <col width="15%" align="center" valign="middle"/>
                           <col width="14%" align="center" valign="middle"/>
                           <col width="14%" align="center" valign="middle"/>
                           <col width="14%" align="center" valign="middle"/>
                           <col width="14%" align="center" valign="middle"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule" align="center">TOUJEO</th>
                                 <th styleCode="Rrule">Total volume</th>
                                 <th styleCode="Rrule">Total units available in presentation</th>
                                 <th styleCode="Rrule">Max dose per injection</th>
                                 <th styleCode="Rrule">Dose increment</th>
                                 <th styleCode="Rrule">NDC number</th>
                                 <th styleCode="Rrule">Package size</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">SoloStar single-patient-use prefilled pen</td>
                                 <td styleCode="Rrule">1.5 mL</td>
                                 <td styleCode="Rrule">450 units</td>
                                 <td styleCode="Rrule">80 units</td>
                                 <td styleCode="Rrule">1 unit</td>
                                 <td styleCode="Rrule">0024-5869-03</td>
                                 <td styleCode="Rrule">3 pens/pack</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Max SoloStar single-patient-use prefilled pen</td>
                                 <td styleCode="Rrule">3 mL</td>
                                 <td styleCode="Rrule">900 units</td>
                                 <td styleCode="Rrule">160 units</td>
                                 <td styleCode="Rrule">2 units</td>
                                 <td styleCode="Rrule">0024-5871-02</td>
                                 <td styleCode="Rrule">2 pens/pack</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Needles are not included in the packs of TOUJEO SoloStar or TOUJEO Max SoloStar single-patient-use prefilled pen.</paragraph>
                        <paragraph>BD (such as BD Ultra-Fine<sup>®</sup>), Ypsomed (such as Clickfine<sup>®</sup>) or Owen Mumford (such as Unifine<sup>®</sup> Pentips<sup>®</sup>) needles<sup>‡</sup> can be used in conjunction with TOUJEO SoloStar or TOUJEO Max SoloStar single-patient-use prefilled pen and are sold separately.</paragraph>
                        <paragraph>A new sterile needle must be attached before each injection. TOUJEO SoloStar or TOUJEO Max SoloStar single-patient-use prefilled pens must never be shared between patients, even if the needle is changed.</paragraph>
                     </text>
                     <effectiveTime value="20240831"/>
                  </section>
               </component>
               <component>
                  <section ID="S16.2">
                     <id root="8e105d84-b218-4324-bfc7-e26f69f9143f"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <title>16.2 Storage</title>
                     <text>
                        <paragraph>Dispense in the original sealed carton with the enclosed Instructions for Use.</paragraph>
                        <paragraph>TOUJEO SoloStar or TOUJEO Max SoloStar prefilled pen should not be stored in the freezer and should not be allowed to freeze. Discard TOUJEO prefilled pen if it has been frozen. Protect TOUJEO SoloStar/TOUJEO Max SoloStar from direct heat and light. </paragraph>
                        <paragraph>Storage conditions are summarized in the following table:</paragraph>
                        <table width="65%">
                           <col width="30%" align="left" valign="top"/>
                           <col width="30%" align="center" valign="top"/>
                           <col width="40%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule" align="center">TOUJEO</th>
                                 <th styleCode="Rrule" valign="middle">Not in-use (unopened) Refrigerated <br/>36°F–46°F (2°C–8°C)</th>
                                 <th styleCode="Rrule" valign="middle">In-use (opened)<footnote ID="f1">To prevent degradation, always store the prefilled pens with the cap on during in-use period. </footnote>
                                    <br/>												Room temperature only<br/>(Do not refrigerate)<br/>up to 86°F (30°C)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">1.5 mL SoloStar single-patient-use prefilled pen</td>
                                 <td styleCode="Rrule">Until expiration date</td>
                                 <td styleCode="Rrule">56 days<footnoteRef IDREF="f1"/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">3 mL Max SoloStar single-patient-use prefilled pen</td>
                                 <td styleCode="Rrule">Until expiration date</td>
                                 <td styleCode="Rrule">56 days<footnoteRef IDREF="f1"/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240831"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="42aed1bd-628f-460b-9b6b-073b0e7aed47"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use). There are separate Instructions for Use for TOUJEO SoloStar and TOUJEO Max SoloStar.</paragraph>
               </text>
               <effectiveTime value="20240831"/>
               <component>
                  <section>
                     <id root="2340f6df-792d-4e85-b920-698796e401c3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Never Share a TOUJEO SoloStar or TOUJEO Max SoloStar Pen Between Patients </content>
                        </paragraph>
                        <paragraph>Advise patients that they must never share TOUJEO SoloStar or TOUJEO Max SoloStar pen with another person even if the needle is changed. Pen sharing poses a risk for transmission of blood-borne pathogens <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240831"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="147419f7-9802-418f-a0b2-8a4a3df4bbab"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hyperglycemia or Hypoglycemia </content>
                        </paragraph>
                        <paragraph>Inform patients that hypoglycemia is the most common adverse reaction with insulin. Inform patients of the symptoms of hypoglycemia (e.g., impaired ability to concentrate and react). This may present a risk in situations where these abilities are especially important, such as driving or operating other machinery. Advise patients who have frequent hypoglycemia or reduced or absent warning signs of hypoglycemia to use caution when driving or operating machinery <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2</linkHtml>, <linkHtml href="#S5.3">5.3)</linkHtml>]</content>.</paragraph>
                        <paragraph>Advise patients that changes in insulin regimen can predispose to hyperglycemia or hypoglycemia and that changes in insulin regimen should be made under close medical supervision <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                        <paragraph>Inform patients that if they change to TOUJEO from other basal insulins they may experience higher average fasting plasma glucose levels in the first weeks of therapy. Advise patients to monitor glucose daily when initiating TOUJEO <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240831"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="fd2021b3-fb5e-4651-b08c-bae69bff3429"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hypoglycemia Due to Medication Errors</content>
                        </paragraph>
                        <paragraph>Instruct patients to always check the insulin label before each injection <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>. The "300 units/mL (U-300)" is highlighted in honey gold on the labels of TOUJEO and TOUJEO Max SoloStar single-patient-use prefilled pens.</paragraph>
                        <paragraph>Inform patients that TOUJEO contains 300 units of insulin glargine per mL (U-300) compared to formulations of insulin glargine that contain 100 units/mL (U-100). To avoid dosing errors and potential overdose, instruct patients to never use a syringe to remove TOUJEO from the TOUJEO SoloStar or TOUJEO Max SoloStar single-patient-use prefilled pen <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>.</paragraph>
                        <paragraph>Inform patients that the dose counter of TOUJEO SoloStar or TOUJEO Max SoloStar single-patient-use prefilled pen shows the number of units of TOUJEO to be injected and no dose recalculation is required <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1</linkHtml>, <linkHtml href="#S2.4">2.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240831"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="460d8a06-d83a-42de-9886-9043b3adc0a1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hypersensitivity Reactions</content>
                        </paragraph>
                        <paragraph>Advise patients that hypersensitivity reactions have occurred with TOUJEO. Inform patients on the symptoms of hypersensitivity reactions <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240831"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="8abdfb73-bba5-4148-a5cf-6bc856d71fb5"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Manufactured by:<br/>sanofi-aventis U.S. LLC<br/>Bridgewater, NJ 08807<br/>A SANOFI COMPANY<br/>U.S. License No. 1752</paragraph>
                  <paragraph>For patent information: https://www.sanofi.us/en/products-and-resources/patents</paragraph>
                  <paragraph>©2024 sanofi-aventis U.S. LLC</paragraph>
                  <paragraph>LANTUS, TOUJEO, SoloStar, and TOUJEO Max SoloStar are registered trademarks of sanofi-aventis U.S. LLC.</paragraph>
                  <paragraph>
                     <sup>‡</sup>Other brands listed are the registered trademarks of their respective owners and are not trademarks of sanofi-aventis U.S. LLC.</paragraph>
               </text>
               <effectiveTime value="20240831"/>
            </section>
         </component>
         <component>
            <section>
               <id root="8992c279-4859-4136-a0b2-a2180f4c0cb1"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <table width="100%">
                     <col width="80%" align="left" valign="top"/>
                     <col width="20%" align="right" valign="top"/>
                     <tfoot>
                        <tr>
                           <td align="left" colspan="2">This Patient Information has been approved by the U.S. Food and Drug Administration<br/>Revised: August 2024</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="center" colspan="2">
                              <paragraph>
                                 <content styleCode="bold">Patient Information<br/>TOUJEO<sup>®</sup> U-300 [too-JAY-oh] <br/>(insulin glargine)<br/>injection,  for subcutaneous use<br/>300 units/mL (U-300)</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <paragraph>
                                 <content styleCode="bold">Do not share your TOUJEO SoloStar<sup>®</sup> or TOUJEO Max SoloStar<sup>®</sup> pen with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <paragraph>
                                 <content styleCode="bold">What is TOUJEO?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>TOUJEO is a long-acting man-made insulin used to control high blood sugar in adults and children who are 6 years of age and older with diabetes mellitus.</item>
                                 <item>TOUJEO is not for the treatment of diabetic ketoacidosis.</item>
                                 <item>It is not known if TOUJEO is safe and effective in children under 6 years of age.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <paragraph>
                                 <content styleCode="bold">Who should not use TOUJEO?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Do not use TOUJEO if you:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>are having an episode of low blood sugar (hypoglycemia).</item>
                                 <item>have an allergy to insulin glargine or any of the ingredients in TOUJEO. See the end of this Patient Information leaflet for a complete list of ingredients in TOUJEO.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <paragraph>
                                 <content styleCode="bold">What should I tell my healthcare provider before using TOUJEO?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Before using TOUJEO, tell your healthcare provider about all your medical conditions, including if you:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>have liver or kidney problems.</item>
                                 <item>take other medicines, especially ones called TZDs (thiazolidinediones).</item>
                                 <item>have heart failure or other heart problems. If you have heart failure, it may get worse while you take TZDs with TOUJEO.</item>
                                 <item>are pregnant, planning to become pregnant, or are breastfeeding. It is not known if TOUJEO may harm your unborn or breastfeeding baby.</item>
                              </list>
                              <paragraph>Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Before you start using TOUJEO, talk to your healthcare provider about low blood sugar and how to manage it.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <paragraph>
                                 <content styleCode="bold">How should I use TOUJEO?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>TOUJEO is available in 2 single-patient-use prefilled pens: TOUJEO SoloStar and TOUJEO Max SoloStar. Your healthcare provider will tell you which TOUJEO pen is right for you.</item>
                                 <item>Read the detailed <content styleCode="bold">Instructions for Use</content> that come with your TOUJEO SoloStar or TOUJEO Max SoloStar single-patient-use prefilled pen.</item>
                                 <item>Use TOUJEO exactly as your healthcare provider tells you to. Your healthcare provider should tell you how much TOUJEO to use and when to use it.</item>
                                 <item>Know the amount of TOUJEO you use. <content styleCode="bold">Do not</content> change the amount of TOUJEO you use unless your healthcare provider tells you to.</item>
                                 <item>Check your insulin label each time you give your injection to make sure you are using the correct insulin.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> use a syringe to remove TOUJEO from your TOUJEO SoloStar or TOUJEO Max SoloStar single-patient-use prefilled pen. This can cause you to give yourself too much insulin. TOUJEO has 3 times as much insulin (300 units/mL) in 1 mL as compared to other insulin glargine products (U-100 units/mL) pens.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> re-use needles. Always use a new needle for each injection. Reusing needles increases your chance of having blocked needles, which can cause you to get the wrong dose of TOUJEO. Using a new needle for each injection also lowers your risk of getting an infection. If your needle is blocked, follow the instructions in <content styleCode="bold">Step 3</content> of the <content styleCode="bold">Instructions for Use</content>.</item>
                                 <item>TOUJEO should be used 1 time each day and at the same time each day.</item>
                                 <item>TOUJEO is injected under the skin (subcutaneously) of your upper legs (thighs), upper arms, or stomach area (abdomen).</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> use TOUJEO in an insulin pump or inject TOUJEO into your vein (intravenously).</item>
                                 <item>
                                    <content styleCode="bold">Change (rotate) your injection sites within the area you choose with each dose</content> to reduce your risk of getting pits or thickening of the skin (lipodystrophy) and lumps in the skin (localized cutaneous amyloidosis)  at the injection sites.<list listType="unordered" styleCode="circle">
                                       <item>
                                          <content styleCode="bold">Do not</content> use the exact same spot for each injection.</item>
                                       <item>
                                          <content styleCode="bold">Do not</content> inject where the skin has pits, is thickened, or has lumps.</item>
                                       <item>
                                          <content styleCode="bold">Do not</content> inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin.</item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not</content> mix TOUJEO with any other type of insulin or liquid medicine.</item>
                                 <item>
                                    <content styleCode="bold">Check your blood sugar levels.</content> Ask your healthcare provider what your blood sugar should be and when you should check your blood sugar levels.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Keep TOUJEO and all medicines out of the reach of children.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <paragraph>
                                 <content styleCode="bold">Your dose of TOUJEO may need to change because of:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>a change in level of physical activity or exercise, weight gain or loss, increased stress, illness, change in diet, or because of other medicines you take.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <paragraph>
                                 <content styleCode="bold">What should I avoid while using TOUJEO?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">While using TOUJEO do not:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>drive or operate heavy machinery, until you know how TOUJEO affects you.</item>
                                 <item>drink alcohol or use over-the-counter medicines that contain alcohol.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <paragraph>
                                 <content styleCode="bold">What are the possible side effects of TOUJEO?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">TOUJEO may cause serious side effects that can lead to death, including:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">low blood sugar (hypoglycemia).</content> Signs and symptoms that may indicate low blood sugar include:<list listType="unordered" styleCode="circle">
                                       <item>dizziness or light-headedness, sweating, confusion, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability or mood change, and hunger.</item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">severe allergic reaction (whole body reaction). Get medical help right away if you have any of these signs or symptoms of a severe allergic reaction:</content>
                                    <list listType="unordered" styleCode="circle">
                                       <item>a rash over your whole body, trouble breathing, a fast heartbeat, or sweating.</item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">low potassium in your blood (hypokalemia).</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">heart failure.</content> Taking certain diabetes pills called TZDs (thiazolidinediones) with TOUJEO may cause heart failure in some people. This can happen even if you have never had heart failure or heart problems before. If you already have heart failure it may get worse while you take TZDs with TOUJEO. Your healthcare provider should monitor you closely while you are taking TZDs with TOUJEO. Tell your healthcare provider if you have any new or worse symptoms of heart failure including:<list listType="unordered" styleCode="circle">
                                       <item>shortness of breath, swelling of your ankles or feet, sudden weight gain.</item>
                                    </list>
                                    <paragraph>Treatment with TZDs and TOUJEO may need to be changed or stopped by your healthcare provider if you have new or worse heart failure.</paragraph>
                                 </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Get emergency medical help if you have:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme drowsiness, dizziness, confusion.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">The most common side effects of TOUJEO include:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>low blood sugar (hypoglycemia), weight gain, itching, rash, swelling, allergic reactions, including reactions at your injection site, skin thickening or pits at the injection site (lipodystrophy).</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">These are not all the possible side effects of TOUJEO.</content> Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <paragraph>
                                 <content styleCode="bold">General information about the safe and effective use of TOUJEO.</content>
                              </paragraph>
                              <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. <content styleCode="bold">Do not</content> use TOUJEO for a condition for which it was not prescribed. <content styleCode="bold">Do not</content> give TOUJEO to other people, even if they have the same symptoms that you have. It may harm them.</paragraph>
                              <paragraph>This Patient Information leaflet summarizes the most important information about TOUJEO. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about TOUJEO that is written for health professionals.</paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients in TOUJEO?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Active ingredient:</content> insulin glargine</item>
                                 <item>
                                    <content styleCode="bold">Inactive ingredients:</content> glycerin, metacresol, zinc and Water for Injection, USP. Hydrochloric acid and sodium hydroxide may be added to adjust the pH.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="2">
                              <paragraph>Manufactured by: sanofi-aventis U.S. LLC, Bridgewater, NJ 08807, A SANOFI COMPANY.<br/>U.S. License No. 1752	<br/>For more information, go to www.TOUJEO.com or call 1-800-633-1610.</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20240831"/>
            </section>
         </component>
         <component>
            <section>
               <id root="6e0da779-08ae-40c8-bd40-86e82a82e36c"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title>Instructions for Use</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">TOUJEO<sup>®</sup> U-300 SoloStar<sup>®</sup> [too-JAY-oh]<br/>(insulin glargine) <br/>injection, for subcutaneous use <br/>300 units/mL (U-300)<br/>1.5 mL single-patient-use prefilled pen</content>
                  </paragraph>
                  <paragraph>Read this first</paragraph>
                  <paragraph>
                     <content styleCode="Bold">Do not share your TOUJEO SoloStar pen with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="Bold">TOUJEO contains 300 units/mL of insulin glargine</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="Bold">Do not re-use needles. </content>If you do, you might not get your dose (underdosing) or get too much (overdosing) as the needle could block.</item>
                     <item>
                        <content styleCode="Bold">Do not use a syringe to remove insulin from your pen. </content>If you do, you will get too much insulin. The scale on most syringes is made for U-100 (non-concentrated) insulin only.</item>
                     <item>The dose selector of your TOUJEO SoloStar pen dials by 1 unit.</item>
                  </list>
                  <paragraph>
                     <content styleCode="Bold">People who are blind or have vision problems should not use the TOUJEO SoloStar pen without help from a person trained to use the TOUJEO SoloStar pen.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="Bold">Important information</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="Bold">Do not </content>use your pen if it is damaged or if you are not sure that it is working properly.</item>
                     <item>Always perform a safety test (see<content styleCode="Bold">
                           <linkHtml href="#step3"> Step 3</linkHtml>
                        </content>).</item>
                     <item>Always carry a spare pen and spare needles in case they are lost or stop working.</item>
                     <item>Change (rotate) your injection sites within the area you choose for each dose (see<content styleCode="Bold"> "<linkHtml href="#PTI">Places to inject</linkHtml>"</content>).</item>
                  </list>
                  <paragraph>
                     <content styleCode="Bold">Learn to inject</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Talk with your healthcare provider about how to inject, before using your pen.</item>
                     <item>Read all of these instructions before using your pen. If you do not follow all of these instructions, you may get too much or too little insulin.</item>
                  </list>
                  <paragraph>
                     <content styleCode="Bold">Need help?</content>
                  </paragraph>
                  <paragraph>If you have any questions about your pen or about diabetes, ask your healthcare provider, go to<content styleCode="Bold"> www.Toujeo.com </content>or call sanofi-aventis at<content styleCode="Bold"> 1-800-633-1610</content>.</paragraph>
                  <paragraph>
                     <content styleCode="Bold">Extra items you will need:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>a new sterile needle (not included with the pen) (see<content styleCode="Bold">
                           <linkHtml href="#step2"> Step 2</linkHtml>
                        </content>).</item>
                     <item>an alcohol swab.</item>
                     <item>a puncture-resistant container for used needles and pens (see <content styleCode="bold">"<linkHtml href="#throw">Throwing your pen away</linkHtml>"</content>).</item>
                  </list>
                  <paragraph ID="PTI">
                     <content styleCode="Bold">Places to inject</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Inject your insulin exactly as your healthcare provider has shown you.</item>
                     <item>Inject your insulin under the skin (subcutaneously) of your upper legs (thighs), upper arms, or stomach area (abdomen).</item>
                     <item>Change (rotate) your injection sites within the area you choose for each dose to reduce your risk of getting pits or thickening of the skin (lipodystrophy) and lumps in the skin (localized cutaneous amyloidosis) at the injection sites.</item>
                     <item>
                        <content styleCode="bold">Do not</content> inject where the skin has pits, is thickened, or has lumps.<list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="Bold">Do not</content> inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin.</item>
                        </list>
                     </item>
                  </list>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM2"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="Bold">Get to know your pen</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM3"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="Bold">Step 1: Check your pen</content>
                  </paragraph>
                  <paragraph>Take a new pen out of the refrigerator at least<content styleCode="Bold"> 1 </content>hour before you inject. Cold insulin is more painful to inject.</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption styleCode="bold">1A</caption>
                        <content styleCode="bold">Check the name and expiration date on the label of your pen.</content>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Make sure you have the correct insulin.</content>
                              <br/>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM4"/>
                              </paragraph>
                           </item>
                           <item>
                              <content styleCode="Bold">Do not </content>use your pen after the expiration date printed on the label.<br/>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM5"/>
                              </paragraph>
                           </item>
                        </list>
                     </item>
                     <item>
                        <caption styleCode="bold">1B</caption>
                        <content styleCode="bold">Pull off the pen cap.</content>
                        <br/>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM6"/>
                        </paragraph>
                     </item>
                     <item>
                        <caption styleCode="bold">1C</caption>
                        <content styleCode="bold">Check that the insulin is clear.</content>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Do not</content> use the pen if the insulin looks cloudy, colored or contains particles.<br/>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM7"/>
                              </paragraph>
                           </item>
                        </list>
                     </item>
                     <item>
                        <caption styleCode="bold">1D</caption>
                        <content styleCode="bold">Wipe the rubber seal with an alcohol swab.</content>
                        <br/>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM8"/>
                        </paragraph>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="Bold">If you have other injector pens</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Making sure you have the correct medicine is especially important if you have other injector pens.</item>
                  </list>
                  <paragraph>
                     <content styleCode="Bold" ID="step2">Step 2: Attach a new needle</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="Bold">Do not </content>re-use needles. Always use a new sterile needle for each injection. This helps stop blocked needles, contamination and infection.</item>
                     <item>Always use needles* from BD (such as BD Ultra-Fine<sup>®</sup>), Ypsomed (such as Clickfine<sup>®</sup>), or Owen Mumford (such as Unifine<sup>® </sup>Pentips<sup>®</sup>).</item>
                  </list>
                  <list listType="unordered">
                     <item>
                        <caption styleCode="bold">2A</caption>
                        <content styleCode="bold">Take a new needle and peel off the protective seal.</content>
                        <br/>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM9"/>
                        </paragraph>
                     </item>
                     <item>
                        <caption styleCode="bold">2B</caption>
                        <content styleCode="bold">Keep the needle straight and screw it onto the pen until fixed. Do not over-tighten.</content>
                        <br/>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM10"/>
                        </paragraph>
                     </item>
                     <item>
                        <caption styleCode="bold">2C</caption>
                        <content styleCode="bold">Pull off the outer needle cap. Keep this for later.</content>
                        <br/>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM11"/>
                        </paragraph>
                     </item>
                     <item>
                        <caption styleCode="bold">2D</caption>
                        <content styleCode="bold">Pull off the inner needle cap and throw away.</content>
                        <br/>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM12"/>
                        </paragraph>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="Bold">Handling needles</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Be careful when you are handling needles to help prevent accidental needle-stick injury. You may give other people a serious infection, or get a serious infection from them.</item>
                  </list>
                  <paragraph>
                     <content styleCode="Bold" ID="step3">Step 3: Do a safety test</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="Bold">Always do a safety test before each injection to:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>check your pen and the needle to make sure they are working properly.</item>
                     <item>make sure that you get the correct insulin dose.</item>
                  </list>
                  <paragraph>If the pen is new, you must perform safety tests before you use the pen for the first time until you see insulin coming out of the needle tip. If you see insulin coming out of the needle tip, the pen is ready to use. If you do not see insulin coming out before taking your dose, you could get an underdose or no insulin at all. This could cause high blood sugar.</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption styleCode="bold">3A</caption>
                        <content styleCode="bold">Select 3 units by turning the dose selector until the dose pointer is at the mark between 2 and 4.</content>
                        <br/>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM13"/>
                        </paragraph>
                     </item>
                     <item>
                        <caption styleCode="bold">3B</caption>
                        <content styleCode="bold">Press the injection button all the way in.</content>
                        <list listType="unordered" styleCode="Disc">
                           <item>When insulin comes out of the needle tip, your pen is working correctly.<br/>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM14"/>
                              </paragraph>
                           </item>
                        </list>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="Bold">If no insulin appears:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>You may need to repeat this step up to 3 times before seeing insulin.</item>
                     <item>If no insulin comes out after the third time, the needle may be blocked. If this happens:<list listType="unordered">
                           <item>
                              <caption>-</caption>change the needle (see <content styleCode="bold">
                                 <linkHtml href="#step6">Step 6</linkHtml>
                              </content> and <content styleCode="bold">
                                 <linkHtml href="#step2">Step 2</linkHtml>
                              </content>),</item>
                           <item>
                              <caption>-</caption>then repeat the safety test (see <content styleCode="bold">
                                 <linkHtml href="#step3">Step 3</linkHtml>
                              </content>).</item>
                        </list>
                     </item>
                     <item>
                        <content styleCode="Bold">Do not </content>use your pen if there is still no insulin coming out of the needle tip. Use a new pen.</item>
                     <item>
                        <content styleCode="Bold">Do not </content>use a syringe to remove insulin from your pen.</item>
                  </list>
                  <paragraph>
                     <content styleCode="Bold">If you see air bubbles</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>You may see air bubbles in the insulin. This is normal, they will not harm you.</item>
                  </list>
                  <paragraph>
                     <content styleCode="Bold">Step 4: Select the dose</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="Bold">Do not </content>select a dose or press the injection button without a needle attached. This may damage your pen.</item>
                     <item>TOUJEO, SoloStar is made to deliver the number of insulin units that your healthcare provider prescribed. You <content styleCode="bold">do not need to do any dose calculations</content>. 							</item>
                     <item>The dose selector of your TOUJEO SoloStar pen dials by 1 unit.</item>
                  </list>
                  <list listType="unordered">
                     <item>
                        <caption styleCode="bold">4A</caption>
                        <content styleCode="bold">Make sure a needle is attached and the dose is set to "0."</content>
                        <br/>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM15"/>
                        </paragraph>
                     </item>
                     <item>
                        <caption styleCode="bold">4B</caption>
                        <content styleCode="bold">Turn the dose selector until the dose pointer lines up with your dose.</content>
                        <list listType="unordered" styleCode="Disc">
                           <item>Set the dose by turning the dose selector to a line in the dose window. Each line equals 1 unit.</item>
                           <item>The dose selector clicks as you turn it. </item>
                           <item>Always check the number in the dose window to make sure you dialed the correct dose.</item>
                           <item>
                              <content styleCode="bold">Do not</content> dial your dose by counting the clicks. You may dial the wrong dose. This may lead to you getting too much insulin or not enough insulin.  </item>
                           <item>If you turn past your dose, you can turn back down.</item>
                           <item>If there are not enough units left in your pen for your dose, the dose selector will stop at the number of units left.</item>
                           <item>If you cannot select your full prescribed dose, split the dose into<content styleCode="Bold"> 2 </content>injections or use a new pen. If you use a new pen, perform a safety test (see <content styleCode="bold">
                                 <linkHtml href="#step3">Step 3</linkHtml>
                              </content>).<paragraph>
                                 <renderMultiMedia referencedObject="MM16"/>
                              </paragraph>
                           </item>
                        </list>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="Bold">How to read the dose window</content>
                  </paragraph>
                  <paragraph>The dose selector dials by 1 unit.</paragraph>
                  <paragraph>Even numbers are shown in line with the dose pointer:</paragraph>
                  <paragraph>           							<renderMultiMedia referencedObject="MM17"/>
                     <br/>
                     <content styleCode="bold">          30 units selected</content>
                  </paragraph>
                  <paragraph>Odd numbers are shown as a line between even numbers:</paragraph>
                  <paragraph>           							<renderMultiMedia referencedObject="MM18"/>
                     <br/>
                     <content styleCode="bold">          29 units selected</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="Bold">Units of insulin in your pen</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Your pen contains a total of<content styleCode="Bold"> 450 </content>units of insulin. You can select doses from<content styleCode="Bold"> 1 </content>to<content styleCode="Bold"> 80 </content>units. Each pen contains more than 1 dose.</item>
                     <item>You can see roughly how many units of insulin are left by looking at where the plunger is on the insulin scale.</item>
                  </list>
                  <paragraph>
                     <content styleCode="Bold">Step 5: Inject your dose</content>
                  </paragraph>
                  <paragraph>If you find it hard to press the injection button in,<content styleCode="Bold"> do not </content>force it as this may break your pen. See the section below for help.</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption styleCode="bold">5A</caption>
                        <content styleCode="bold">Choose a place to inject as shown in the picture labeled "Places to inject."</content>
                        <list listType="unordered" styleCode="Disc">
                           <item>The site you choose for the injection should be clean and dry.</item>
                           <item>If your skin is dirty, clean it as instructed by your healthcare provider.</item>
                        </list>
                     </item>
                     <item>
                        <caption styleCode="bold">5B</caption>
                        <content styleCode="bold">Push the needle into your skin as shown by your healthcare provider.</content>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Do not</content> touch the injection button yet.<br/>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM19"/>
                              </paragraph>
                           </item>
                        </list>
                     </item>
                     <item>
                        <caption styleCode="bold">5C</caption>
                        <content styleCode="bold">Place your thumb on the injection button. Then press all the way in and hold.</content>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="Bold">Do not </content>press at an angle. Your thumb could block the dose selector from turning.<br/>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM20"/>
                              </paragraph>
                           </item>
                        </list>
                     </item>
                     <item>
                        <caption styleCode="bold">5D</caption>
                        <content styleCode="bold">Keep the injection button held in and when you see "0" in the dose window, slowly count to 5.</content>
                        <list listType="unordered" styleCode="Disc">
                           <item>This will make sure you get your full dose.<br/>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM21"/>
                              </paragraph>
                           </item>
                        </list>
                     </item>
                     <item>
                        <caption styleCode="bold">5E</caption>
                        <content styleCode="bold">After holding and slowly counting to 5, release the injection button. Then remove the needle from your skin.</content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="Bold">If you find it hard to press the injection button in:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Change the needle (see<content styleCode="bold">
                           <linkHtml href="#step6"> Step 6 </linkHtml>
                        </content>and<content styleCode="bold">
                           <linkHtml href="#step2"> Step 2</linkHtml>
                        </content>) then do a safety test (see<content styleCode="bold">
                           <linkHtml href="#step3"> Step 3</linkHtml>
                        </content>).</item>
                     <item>If you still find it hard to press in, get a new pen.</item>
                     <item>Do not use a syringe to remove insulin from your pen.</item>
                  </list>
                  <paragraph>
                     <content styleCode="Bold" ID="step6">Step 6: Remove the needle</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="bold">Take care when handling needles to prevent needle injury and cross-infection.</content>
                     </item>
                     <item>
                        <content styleCode="Bold">Do not put the inner needle cap back on.</content>
                     </item>
                  </list>
                  <list listType="unordered">
                     <item>
                        <caption styleCode="bold">6A</caption>
                        <content styleCode="bold">Grip the widest part of the outer needle cap. Keep the needle straight and guide it into the outer needle cap.<br/>Then push firmly on.</content>
                        <list listType="unordered" styleCode="Disc">
                           <item>The needle can puncture the cap if it is recapped at an angle.<br/>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM22"/>
                              </paragraph>
                           </item>
                        </list>
                     </item>
                     <item>
                        <caption styleCode="bold">6B</caption>
                        <content styleCode="bold">Grip and squeeze the widest part of the outer needle cap. Turn your pen several times with your other hand to remove the needle.</content>
                        <list listType="unordered" styleCode="Disc">
                           <item>Try again if the needle does not come off the first time.<br/>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM23"/>
                              </paragraph>
                           </item>
                        </list>
                     </item>
                     <item>
                        <caption styleCode="bold">6C</caption>
                        <content styleCode="bold">Throw away the used needle in a puncture-resistant container </content>(see <content styleCode="Bold">"<linkHtml href="#throw">Throwing your pen away</linkHtml>"</content> at the end of this Instructions for Use).<br/>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM24"/>
                        </paragraph>
                     </item>
                     <item>
                        <caption styleCode="bold">6D</caption>
                        <content styleCode="bold">Put the pen cap back on.</content>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Do not</content> put the pen back in the refrigerator.<br/>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM25"/>
                              </paragraph>
                           </item>
                        </list>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="Bold">Use by</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Only use your pen for up to <content styleCode="Bold">56 days </content>after its first use.</item>
                  </list>
                  <paragraph>
                     <content styleCode="Bold">How to store your pen </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="Bold">Before first use</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Keep new pens in the refrigerator between<content styleCode="Bold"> 36°F and 46°F (2°C and 8°C).</content>
                     </item>
                     <item>
                        <content styleCode="Bold">Do not </content>freeze. Throw away your pen if it has been frozen (See "<content styleCode="bold">
                           <linkHtml href="#throw">Throwing your pen away</linkHtml>
                        </content>").</item>
                  </list>
                  <paragraph>
                     <content styleCode="Bold">After first use</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Keep your pen at room temperature<content styleCode="Bold"> up to 86°F (30°C)</content>. 							</item>
                     <item>Protect your pen from direct heat and light.</item>
                     <item>
                        <content styleCode="Bold">Do not </content>put your pen back in the refrigerator.</item>
                     <item>
                        <content styleCode="Bold">Do not </content>store your pen with the needle attached.</item>
                     <item>Store your pen with the pen cap on.</item>
                     <item>Keep TOUJEO SoloStar pens and needles out of the reach of children.</item>
                  </list>
                  <paragraph>
                     <content styleCode="Bold">How to care for your pen</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="Bold">Handle your pen with care</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="bold">Do not</content> drop your pen or knock it against hard surfaces.</item>
                     <item>If you think that your pen may be damaged,<content styleCode="Bold"> do not </content>try to fix it. Use a new one.</item>
                  </list>
                  <paragraph>
                     <content styleCode="Bold">Protect your pen from dust and dirt</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>You can clean the outside of your pen by wiping it with a damp cloth (water only).<content styleCode="Bold"> Do not </content>soak, wash or lubricate your pen. This may damage it.</item>
                  </list>
                  <paragraph>
                     <content styleCode="Bold" ID="throw">Throwing your pen away</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>The used TOUJEO SoloStar pen may be thrown away in your household trash after you have removed the needle.</item>
                     <item>Put the used needle in a FDA-cleared sharps disposal container right away after use.<br/>
                        <content styleCode="Bold">Do not </content>throw away (dispose of) needles in your household trash.</item>
                     <item>If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:<list listType="unordered">
                           <item>
                              <caption>–</caption>made of a heavy-duty plastic,</item>
                           <item>
                              <caption>–</caption>can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,</item>
                           <item>
                              <caption>–</caption>upright and stable during use,</item>
                           <item>
                              <caption>–</caption>leak-resistant, and</item>
                           <item>
                              <caption>–</caption>properly labeled to warn of hazardous waste inside the container.</item>
                        </list>
                     </item>
                     <item>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal.</item>
                     <item>
                        <content styleCode="Bold">Do not </content>dispose of your used sharps disposal container in your household trash unless your community guidelines permit this.<content styleCode="Bold"> Do not </content>recycle your used sharps disposal container.</item>
                  </list>
                  <paragraph>Manufactured by:<br/>sanofi-aventis U.S. LLC<br/>Bridgewater, NJ 08807<br/>A SANOFI COMPANY<br/>U.S. License No. 1752</paragraph>
                  <paragraph>©2024 sanofi-aventis U.S. LLC</paragraph>
                  <paragraph>TOUJEO and SoloStar are registered trademarks of sanofi-aventis U.S. LLC.</paragraph>
                  <paragraph>Other brands listed are the registered trademarks of their respective owners and are not trademarks of sanofi-aventis U.S. LLC.</paragraph>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>Revised: August 2024</paragraph>
               </text>
               <effectiveTime value="20240831"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM4">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM6">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM7">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM8">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM9">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM10">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM11">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM12">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM13">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-13.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM14">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-14.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM15">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-15.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM16">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-16.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM17">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-17.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM18">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-18.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM19">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-19.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM20">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-20.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM21">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-21.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM22">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-22.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM23">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-23.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM24">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-24.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM25">
                     <text>figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-25.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="35bbf7d0-13df-455a-868c-32523a4cbb8a"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title>Instructions for Use</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">TOUJEO U-300 Max SoloStar<sup>®</sup> [too-JAY-oh]<br/> (insulin glargine) <br/>injection, for subcutaneous use<br/>300 units/mL (U-300)<br/>3 mL single-patient-use prefilled pen</content>
                  </paragraph>
                  <paragraph>Read this first</paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not share your TOUJEO Max SoloStar pen with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">TOUJEO contains 300 units/mL of insulin glargine</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>
                        <content styleCode="bold">Do not re-use needles.</content> If you do, you might not get your dose (underdosing) or get too much (overdosing) as the needle could block.</item>
                     <item>
                        <content styleCode="bold">Do not use a syringe to remove insulin from your pen.</content> If you do, you will get too much insulin. The scale on most syringes is made for U-100 (non-concentrated) insulin only.</item>
                     <item>The dose selector of your TOUJEO Max SoloStar pen dials by <content styleCode="bold">2 units</content>.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">People who are blind or have vision problems should not use the TOUJEO Max SoloStar pen without help from a person trained to use the TOUJEO Max SoloStar pen.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Important information</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>
                        <content styleCode="bold">Do not</content> use your pen if it is damaged or if you are not sure that it is working properly.</item>
                     <item>Always perform a safety test (see <content styleCode="bold">
                           <linkHtml href="#step3a">Step 3</linkHtml>
                        </content>).</item>
                     <item>Always carry a spare pen and spare needles in case they are lost or stop working.</item>
                     <item>Change (rotate) your injection sites within the area you choose for each dose (see <content styleCode="bold">"<linkHtml href="#PTI2">Places to inject</linkHtml>"</content>).</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Learn to inject</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Talk with your healthcare provider about how to inject, before using your pen.</item>
                     <item>Read all of these instructions before using your pen. If you do not follow all of these instructions, you may get too much or too little insulin.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Need help?</content>
                  </paragraph>
                  <paragraph>If you have any questions about your pen or about diabetes, ask your healthcare provider, go to <content styleCode="bold">www.Toujeo.com</content> or call sanofi-aventis at <content styleCode="bold">1-800-633-1610</content>.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Extra items you will need:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>a new sterile needle (not included with the pen) (see <content styleCode="bold">
                           <linkHtml href="#step2a">Step 2</linkHtml>
                        </content>).</item>
                     <item>an alcohol swab.</item>
                     <item>a puncture-resistant container for used needles and pens (see <content styleCode="bold">									"<linkHtml href="#throwing">Throwing your pen away</linkHtml>"</content>).</item>
                  </list>
                  <paragraph ID="PTI2">
                     <content styleCode="bold">Places to inject</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Inject your insulin exactly as your healthcare provider has shown you.</item>
                     <item>Inject your insulin under the skin (subcutaneously) of your upper legs (thighs), upper arms, or stomach area (abdomen).</item>
                     <item>Change (rotate) your injection sites within the area you choose for each dose to reduce your risk of getting pits or thickening of the skin (lipodystrophy) and lumps in the skin (localized cutaneous amyloidosis) at the injection sites.</item>
                     <item>
                        <content styleCode="bold">Do not</content> inject where the skin has pits, is thickened, or has lumps.<list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Do not</content> inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin.<br/>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM26"/>
                              </paragraph>
                           </item>
                        </list>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Get to know your pen</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM27"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Step 1: Check your pen</content>
                  </paragraph>
                  <paragraph>Take a new pen out of the refrigerator at least <content styleCode="bold">1</content> hour before you inject. Cold insulin is more painful to inject.</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption styleCode="bold">1A</caption>
                        <content styleCode="bold">Check the name and expiration date on the label of your pen.</content>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="bold">Make sure you have the correct insulin.</content>
                              <br/>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM28"/>
                              </paragraph>
                           </item>
                           <item>
                              <content styleCode="bold">Do not</content> use your pen after the expiration date printed on the label.<br/>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM29"/>
                              </paragraph>
                           </item>
                        </list>
                     </item>
                     <item>
                        <caption styleCode="bold">1B</caption>
                        <content styleCode="bold">Pull off the pen cap.</content>
                        <br/>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM30"/>
                        </paragraph>
                     </item>
                     <item>
                        <caption styleCode="bold">1C</caption>
                        <content styleCode="bold">Check that the insulin is clear.</content>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="bold">Do not</content> use the pen if the insulin looks cloudy, colored or contains particles.<br/>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM31"/>
                              </paragraph>
                           </item>
                        </list>
                     </item>
                     <item>
                        <caption styleCode="bold">1D</caption>
                        <content styleCode="bold">Wipe the rubber seal with an alcohol swab.</content>
                        <br/>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM32"/>
                        </paragraph>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">If you have other injector pens</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Making sure you have the correct medicine is especially important if you have other injector pens.</item>
                  </list>
                  <paragraph ID="step2a">
                     <content styleCode="bold">Step 2: Attach a new needle</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>
                        <content styleCode="bold">Do not</content> re-use needles. Always use a new sterile needle for each injection. This helps stop blocked needles, contamination and infection.</item>
                     <item>Always use needles* from BD (such as BD Ultra-Fine<sup>®</sup>), Ypsomed (such as Clickfine<sup>®</sup>), or Owen Mumford (such as Unifine<sup>®</sup> Pentips<sup>®</sup>) that are 8 mm long or shorter.</item>
                  </list>
                  <list listType="unordered">
                     <item>
                        <caption styleCode="bold">2A</caption>
                        <content styleCode="bold">Take a new needle and peel off the protective seal.</content>
                        <br/>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM33"/>
                        </paragraph>
                     </item>
                     <item>
                        <caption styleCode="bold">2B</caption>
                        <content styleCode="bold">Keep the needle straight and screw it onto the pen until fixed. Do not over-tighten.</content>
                        <br/>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM34"/>
                        </paragraph>
                     </item>
                     <item>
                        <caption styleCode="bold">2C</caption>
                        <content styleCode="bold">Pull off the outer needle cap. Keep this for later.</content>
                        <br/>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM35"/>
                        </paragraph>
                     </item>
                     <item>
                        <caption styleCode="bold">2D</caption>
                        <content styleCode="bold">Pull off the inner needle cap and throw away.</content>
                        <br/>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM36"/>
                        </paragraph>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Handling needles</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Be careful when you are handling needles to help prevent accidental needle-stick injury. You may give other people a serious infection, or get a serious infection from them.</item>
                  </list>
                  <paragraph ID="step3a">
                     <content styleCode="bold">Step 3: Do a safety test</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Always do a safety test before each injection to:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>check your pen and the needle to make sure they are working properly.</item>
                     <item>make sure that you get the correct insulin dose.</item>
                  </list>
                  <paragraph>If the pen is new, you must perform safety tests before you use the pen for the first time until you see insulin coming out of the needle tip. If you see insulin coming out of the needle tip, the pen is ready to use. If you do not see insulin coming out before taking your dose, you could get an underdose or no insulin at all. This could cause high blood sugar.</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption styleCode="bold">3A</caption>
                        <content styleCode="bold">Select 4 units by turning the dose selector until the dose pointer is at the 4 mark.</content>
                        <br/>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM37"/>
                        </paragraph>
                     </item>
                     <item>
                        <caption styleCode="bold">3B</caption>
                        <content styleCode="bold">Press the injection button all the way in.</content>
                        <list listType="unordered" styleCode="disc">
                           <item>When insulin comes out of the needle tip, your pen is working correctly.<br/>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM38"/>
                              </paragraph>
                           </item>
                        </list>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">If no insulin appears:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>You may need to repeat this step up to 6 times before seeing insulin. 									</item>
                     <item>If no insulin comes out after the sixth time, the needle may be blocked. If this happens:<list listType="unordered">
                           <item>
                              <caption>–</caption>change the needle (see <content styleCode="bold">
                                 <linkHtml href="#step6a">Step 6</linkHtml>
                              </content> and <content styleCode="bold">
                                 <linkHtml href="#step2a">Step 2</linkHtml>
                              </content>),</item>
                           <item>
                              <caption>–</caption>then repeat the safety test (see <content styleCode="bold">
                                 <linkHtml href="#step3a">Step 3</linkHtml>
                              </content>).</item>
                        </list>
                     </item>
                     <item>
                        <content styleCode="bold">Do not</content> use your pen if there is still no insulin coming out of the needle tip. Use a new pen.</item>
                     <item>
                        <content styleCode="bold">Do not</content> use a syringe to remove insulin from your pen.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">If you see air bubbles</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>You may see air bubbles in the insulin. This is normal, they will not harm you.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Step 4: Select the dose</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>
                        <content styleCode="bold">Do not</content> select a dose or press the injection button without a needle attached. This may damage your pen.</item>
                     <item>TOUJEO Max SoloStar is made to deliver the number of insulin units that your healthcare provider prescribed. You <content styleCode="bold">do not need to do any dose calculations</content>. 							</item>
                     <item>The dose selector of your TOUJEO Max SoloStar pen dials by 2 units and can only dial even doses of insulin.</item>
                  </list>
                  <list listType="unordered">
                     <item>
                        <caption styleCode="bold">4A</caption>
                        <content styleCode="bold">Make sure a needle is attached and the dose is set to "0."</content>
                        <br/>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM39"/>
                        </paragraph>
                     </item>
                     <item>
                        <caption styleCode="bold">4B</caption>
                        <content styleCode="bold">Turn the dose selector until the dose pointer lines up with your dose.</content>
                        <list listType="unordered" styleCode="disc">
                           <item>Set the dose by turning the dose selector to a line in the dose window. Each line equals 2 units.</item>
                           <item>The dose selector clicks as you turn it.</item>
                           <item>Always check the number in the dose window to make sure you dialed the correct dose.</item>
                           <item>
                              <content styleCode="bold">Do not</content> dial your dose by counting the clicks. You may dial the wrong dose. This may lead to you getting too much insulin or not enough insulin.</item>
                           <item>If you turn past your dose, you can turn back down.</item>
                           <item>If there are not enough units left in your pen for your dose, the dose selector will stop at the number of units left.</item>
                           <item>If you cannot select your full prescribed dose, split the dose into <content styleCode="bold">2</content> injections or use a new pen. If you use a new pen, perform a safety test (see <content styleCode="bold">
                                 <linkHtml href="#step3a">Step 3</linkHtml>
                              </content>).<br/>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM40"/>
                              </paragraph>
                           </item>
                        </list>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">How to read the dose window</content>
                  </paragraph>
                  <paragraph>The dose selector dials by 2 units.</paragraph>
                  <paragraph>Each line in the dose window is an even number.</paragraph>
                  <paragraph>          							<renderMultiMedia referencedObject="MM41"/>
                     <br/>              <content styleCode="bold">60 units selected</content>
                  </paragraph>
                  <paragraph>          							<renderMultiMedia referencedObject="MM42"/>
                     <br/>              <content styleCode="bold">58 units selected</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Units of insulin in your pen</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Your pen contains a total of <content styleCode="bold">900</content> units of insulin. You can select doses from <content styleCode="bold">2</content> to <content styleCode="bold">160</content> units. The dose is adjusted by 2 units at a time. Each pen contains more than 1 dose.</item>
                     <item>You can see roughly how many units of insulin are left by looking at where the plunger is on the insulin scale.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Step 5: Inject your dose</content>
                  </paragraph>
                  <paragraph>If you find it hard to press the injection button in, <content styleCode="bold">do not</content> force it as this may break your pen. See the section below for help.</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption styleCode="bold">5A</caption>
                        <content styleCode="bold">Choose a place to inject as shown in the picture labeled "Places to inject."</content>
                        <list listType="unordered" styleCode="disc">
                           <item>The site you choose for the injection should be clean and dry.</item>
                           <item>If your skin is dirty, clean it as instructed by your healthcare provider.</item>
                        </list>
                     </item>
                     <item>
                        <caption styleCode="bold">5B</caption>
                        <content styleCode="bold">Push the needle into your skin as shown by your healthcare provider.</content>
                        <list listType="unordered">
                           <item>
                              <content styleCode="bold">Do not</content> touch the injection button yet.<br/>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM43"/>
                              </paragraph>
                           </item>
                        </list>
                     </item>
                     <item>
                        <caption styleCode="bold">5C</caption>
                        <content styleCode="bold">Place your thumb on the injection button. Then press all the way in and hold.</content>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="bold">Do not</content> press at an angle. Your thumb could block the dose selector from turning.<br/>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM44"/>
                              </paragraph>
                           </item>
                        </list>
                     </item>
                     <item>
                        <caption styleCode="bold">5D</caption>
                        <content styleCode="bold">Keep the injection button held in and when you see "0" in the dose window, slowly count to 5.</content>
                        <list listType="unordered" styleCode="disc">
                           <item>This will make sure you get your full dose.<br/>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM45"/>
                              </paragraph>
                           </item>
                        </list>
                     </item>
                     <item>
                        <caption styleCode="bold">5E</caption>
                        <content styleCode="bold">After holding and slowly counting to 5, release the injection button. Then remove the needle from your skin.</content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">If you find it hard to press the injection button in:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Change the needle (see <content styleCode="bold">
                           <linkHtml href="#step6a">Step 6</linkHtml>
                        </content> and <content styleCode="bold">
                           <linkHtml href="#step2a">Step 2</linkHtml>
                        </content>) then do a safety test (see <content styleCode="bold">
                           <linkHtml href="#step3a">Step 3</linkHtml>
                        </content>).</item>
                     <item>If you still find it hard to press in, get a new pen.</item>
                     <item>
                        <content styleCode="bold">Do not</content> use a syringe to remove insulin from your pen.</item>
                  </list>
                  <paragraph ID="step6a">
                     <content styleCode="bold">Step 6: Remove the needle</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Take care when handling needles to prevent needle injury and cross-infection.</item>
                     <item>
                        <content styleCode="bold">Do not</content> put the inner needle cap back on.</item>
                  </list>
                  <list listType="unordered">
                     <item>
                        <caption styleCode="bold">6A</caption>
                        <content styleCode="bold">Grip the widest part of the outer needle cap. Keep the needle straight and guide it into the outer needle cap.<br/>Then push firmly on.</content>
                        <list listType="unordered" styleCode="disc">
                           <item>The needle can puncture the cap if it is recapped at an angle.<br/>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM46"/>
                              </paragraph>
                           </item>
                        </list>
                     </item>
                     <item>
                        <caption styleCode="bold">6B</caption>
                        <content styleCode="bold">Grip and squeeze the widest part of the outer needle cap. Turn your pen several times with your other hand to remove the needle.</content>
                        <list listType="unordered" styleCode="disc">
                           <item>Try again if the needle does not come off the first time.<br/>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM47"/>
                              </paragraph>
                           </item>
                        </list>
                     </item>
                     <item>
                        <caption styleCode="bold">6C</caption>
                        <content styleCode="bold">Throw away the used needle in a puncture-resistant container </content>(see <content styleCode="bold">									"<linkHtml href="#throwing">Throwing your pen away</linkHtml>"</content> at the end of this Instructions for Use).<br/>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM48"/>
                        </paragraph>
                     </item>
                     <item>
                        <caption styleCode="bold">6D</caption>
                        <content styleCode="bold">Put the pen cap back on.</content>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="bold">Do not</content> put the pen back in the refrigerator.<br/>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM49"/>
                              </paragraph>
                           </item>
                        </list>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Use by</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Only use your pen for up to <content styleCode="bold">56 days</content> after its first use.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">How to store your pen</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Before first use</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Keep new pens in the refrigerator between <content styleCode="bold">36°F and 46°F (2°C and 8°C)</content>.</item>
                     <item>
                        <content styleCode="bold">Do not</content> freeze. Throw away your pen if it has been frozen (see <content styleCode="bold">									"<linkHtml href="#throwing">Throwing your pen away</linkHtml>"</content>).</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">After first use</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Keep your pen at room temperature <content styleCode="bold">up to 86°F (30°C)</content>.</item>
                     <item>Protect your pen from direct heat and light.</item>
                     <item>
                        <content styleCode="bold">Do not</content> put your pen back in the refrigerator.</item>
                     <item>
                        <content styleCode="bold">Do not</content> store your pen with the needle attached.</item>
                     <item>Store your pen with the pen cap on.</item>
                     <item>Keep TOUJEO Max SoloStar pens and needles out of the reach of children.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">How to care for your pen</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Handle your pen with care</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>
                        <content styleCode="bold">Do not</content> drop your pen or knock it against hard surfaces.</item>
                     <item>If you think that your pen may be damaged, <content styleCode="bold">do not</content> try to fix it. Use a new one.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Protect your pen from dust and dirt</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>You can clean the outside of your pen by wiping it with a damp cloth (water only). <content styleCode="bold">Do not</content> soak, wash or lubricate your pen. This may damage it.</item>
                  </list>
                  <paragraph ID="throwing">
                     <content styleCode="bold">Throwing your pen away</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>The used TOUJEO Max SoloStar pen may be thrown away in your household trash after you have removed the needle.</item>
                     <item>Put the used needle in a FDA-cleared sharps disposal container right away after use. <content styleCode="bold">Do not</content> throw away (dispose of) needles in your household trash.</item>
                     <item>If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:<list listType="unordered">
                           <item>
                              <caption>–</caption>made of a heavy-duty plastic,</item>
                           <item>
                              <caption>–</caption>can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,</item>
                           <item>
                              <caption>–</caption>upright and stable during use,</item>
                           <item>
                              <caption>–</caption>leak-resistant, and</item>
                           <item>
                              <caption>–</caption>properly labeled to warn of hazardous waste inside the container.</item>
                        </list>
                     </item>
                     <item>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at:<br/>http://www.fda.gov/safesharpsdisposal.</item>
                     <item>
                        <content styleCode="bold">Do not</content> dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. <content styleCode="bold">Do not</content> recycle your used sharps disposal container.</item>
                  </list>
                  <paragraph>Manufactured by:<br/>sanofi-aventis U.S. LLC<br/>Bridgewater, NJ 08807<br/>A SANOFI COMPANY<br/>U.S. License No. 1752</paragraph>
                  <paragraph>©2024 sanofi-aventis U.S. LLC</paragraph>
                  <paragraph>TOUJEO and TOUJEO Max SoloStar are registered trademarks of sanofi-aventis U.S. LLC.</paragraph>
                  <paragraph>Other brands listed are the registered trademarks of their respective owners and are not trademarks of sanofi-aventis U.S. LLC.</paragraph>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>Revised: August 2024</paragraph>
               </text>
               <effectiveTime value="20240831"/>
               <component>
                  <observationMedia ID="MM26">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-26.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM27">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-27.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM28">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-28.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM29">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-29.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM30">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-30.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM31">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-31.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM32">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-32.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM33">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-33.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM34">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-34.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM35">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-35.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM36">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-36.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM37">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-37.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM38">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-38.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM39">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-39.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM40">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-40.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM41">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-41.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM42">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-42.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM43">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-43.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM44">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-44.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM45">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-45.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM46">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-46.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM47">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-47.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM48">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-48.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM49">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-49.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="0873b0a7-1f99-413c-ab0e-85c6dc8b0c5f"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 1.5 mL Pen Carton</title>
               <text>
                  <paragraph>NDC 0024-5869-03<br/>Rx only</paragraph>
                  <paragraph>Toujeo<sup>®</sup> SoloStar<sup>®</sup>
                     <br/>(insulin glargine) injection</paragraph>
                  <paragraph>For Single Patient Use Only </paragraph>
                  <paragraph>300 units/mL (U-300)</paragraph>
                  <paragraph>For subcutaneous use only <br/>Solution for injection in a disposable insulin delivery device <br/>Do not remove insulin with syringe <br/>Always use a new needle – Do not mix with other insulins <br/>Use only if solution is clear and colorless with no particles visible</paragraph>
                  <paragraph>Use within 56 days after opening <br/>*Needles not included (see back panel) <br/>Three 1.5 mL prefilled pens – Dispense in this sealed carton</paragraph>
                  <paragraph>sanofi</paragraph>
                  <renderMultiMedia referencedObject="MM50"/>
               </text>
               <effectiveTime value="20240831"/>
               <component>
                  <observationMedia ID="MM50">
                     <text>PRINCIPAL DISPLAY PANEL - 1.5 mL Pen Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-50.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="c204562c-653d-43d0-b0a0-c9b767d03773"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 3 mL Pen Carton</title>
               <text>
                  <paragraph>NDC 0024-5871-02<br/>Rx only</paragraph>
                  <paragraph>Toujeo Max SoloStar<sup>®</sup>
                     <br/>(insulin glargine) injection</paragraph>
                  <paragraph>For Single Patient Use Only </paragraph>
                  <paragraph>300 units/mL (U-300) <br/>Adjusts by 2 units</paragraph>
                  <paragraph>For subcutaneous use only <br/>Solution for injection in a disposable insulin delivery device <br/>Do not remove insulin with syringe <br/>Always use a new needle – Do not mix with other insulins <br/>Use only if solution is clear and colorless with no particles visible</paragraph>
                  <paragraph>Use within 56 days after opening <br/>*Needles not included (see back panel) <br/>Two 3 mL prefilled pens – Dispense in this sealed carton</paragraph>
                  <paragraph>sanofi</paragraph>
                  <renderMultiMedia referencedObject="MM51"/>
               </text>
               <effectiveTime value="20240831"/>
               <component>
                  <observationMedia ID="MM51">
                     <text>PRINCIPAL DISPLAY PANEL - 3 mL Pen Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="c9561d96-124d-48ca-982f-0aa1575bff36-51.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>